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The Policy Research Unit in Economic Evaluation of Health and Care interventions is funded by the 
Department of Health Policy Research Programme. It is a collaboration between researchers from 
the University of Sheffield and the University of York.  
The Department of Health's Policy Research Unit in Economic Evaluation of Health and Care 
Interventions is a 7 year programme of work that started in January 2011.  The unit is led by 
Professor John Brazier (Director, University of Sheffield) and Professor Mark Sculpher (Deputy 
Director, University of York) with the aim of assisting policy makers in the Department of Health to 
improve the allocation of resources in health and social care. 
This is an independent report commissioned and funded by the Policy Research Programme in the 
Department of Health. The views expressed are not necessarily those of the Department. 
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Acronym Definition 
AE Adverse events 
ANOVA Analysis of variance 
CAI Clinical activity index   
CD ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ 
CDAI ƌŽŚŶ ?Ɛdisease activity index 
CDI ŚŝůĚƌĞŶ ?ƐĚĞƉƌĞƐƐŝŽŶŝŶǀĞŶƚŽƌǇ WShort form 
CGQL Cleveland Global Quality of Life 
CHQ Child Health Questionnaire 
CHQ-CF87 Child Health Questionnaire  W child form 87 
CHQ-PF50 Child Health Questionnaire  W Parent form 50 
CHU-9D Child Health Utility 9D 
CLIQ ƌŽŚŶ ?Ɛ>ŝĨĞ/ŵƉĂĐƚYƵĞƐƚŝŽŶŶĂŝƌĞ 
DH Department of Health 
EMA European Medicines Agency 
EEPRU Policy Research Unit in Economic Evaluation of Health and Care Interventions 
EQ-5D (-3L) EuroQol 5 dimensions 
EQ-5D-5L EuroQol-5D-5 levels 
EQ-5D-Y EuroQol-5D  youth version 
ES Effect size 
FR Future research 
GI Gastrointestinal 
HRQoL Health related quality of life   
HS Health states 
HTA Health technology assessment 
HUI2 Health Utility Index mark 2 
IBD Inflammatory bowel disease 
IBDQ-9 Inflammatory bowel disease questionnaire-9 
IBDQ-32 Inflammatory bowel disease questionnaire-32 
IBDQOL Inflammatory bowel disease quality of life questionnaire 
IBDSI Inflammatory bowel disease stress index 
ICC Intraclass correlation coefficient 
ICF 
World Health Organization's International Classification of Functioning, Disability and 
Health 
MTA Multiple technology assessment 
N or n Number 
NCA National Clinical Audit 
NHP Nottingham Health Profile 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 
PCDAI WĂĞĚŝĂƚƌŝĐƌŽŚŶ ?ƐĚŝƐĞĂƐĞĂĐƚŝǀŝƚǇŝŶĚĞǆ 
PedsQL Paediatric quality of life inventory 
PedsQL 
MFS 
Paediatric quality of life inventory - Multidimensional Fatigue Scale 
PedsQL GI Paediatric quality of life inventory  W gastrointestinal module 
PR Parent/carer report 
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PR Potential recommendations 
PRO2 Patient reported outcome 2 
PRO3 Patient reported outcome 3 
PROM(s) patient reported outcome measure(s) 
QALY Quality adjusted life year 
R&D Research and development 
RFIPC Rating Form of IBD Patient Concerns 
RCT(s) Randomised controlled trial(s) 
SF-36 Short form 36 
SIBDQ Short Inflammatory Bowel Disease Questionnaire 
SR Self report 
SRM Standardised response mean 
STA Single technology assessment 
TA(s) Technology Appraisal(s) 
TAG Technology Assessment group 
TTO Time trade off 
UC Ulcerative colitis 
UK United Kingdom 
UK-IBD-Q IBD-Control, quality of life 
VAS Visual analogue scale 
WP Work package 
WPAI: CD Work Productivity and Activity Impairment: Crohn's Disease 
EEPRU NCA Appendix C: IŶĨůĂŵŵĂƚŽƌǇ Bowel 
Disease Page 6 
1. BACKGROUND
The Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) was 
approached by Jason Cox (Research and Development (R&D) Division) to prepare a programme of 
research to support the appropriateness of, and use of, patient reported outcome measures 
(PROMs) collected for the National Clinical Audit (NCA).  The EEPRU programme was informed by a 
R&D template prepared by Simon Bennett, Steve Fairman and Keith Willett at National Health 
Service (NHS) England. 
The purpose of introducing PROMs into the NCA programme is to be able to 1) compare 
performance between providers and commissioners in the NHS, 2) compare the cost-effectiveness 
of alternative providers in delivering the specific services (i.e. linking outcomes and resource use), 
and 3) assess the cost-effectiveness of alternative interventions and other changes in the NHS.  The 
intention is to introduce PROMs across a range of conditions over the next 3 years commencing with 
13 conditions in the 2014/15 NCA programme.  
The agreed research programme consists of 3 concurrent work packages (WP) as described in the 
document submitted to the Department of Health (DH) (8
th
 November 2013).  The current document 
provides details on the objectives, methodology and results for Work Package 1 (WP1): to determine 
what PROMS should be used in the 13 health conditions specified in the 2014/15 NCA programme. 
2. OVERVIEW
WP1 is split into three separate components consisting of: 
WP1.1 To examine whether the EuroQol-5D (EQ-5D) is appropriate in the 13 health conditions 
specified in the 2013/14 NCA programme.  
WP1.2 To identify what measure could be used when the EQ-5D is not appropriate in the 13 health 
conditions, taking into account that the proposed measure would be used to generate 
preference-based utility measures (either directly through existing preference-based weights, 
or indirectly through existing mapping functions suitable for the proposed measure). 
WP1.3 To identify the evidence required to address questions of cost-effectiveness using the NCA 
data. 
Each component consists of a series of reviews of the literature. 
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This Appendix provides the detailed results for the condition iŶĨůĂŵŵĂƚŽƌǇ bowel disease (IBD) and 
should be read in conjunction with both the main report and the methods/search strategy 
appendices. 
3. METHOD
The full detailed methodology used is provided in Appendix A and B, including the search strategy, 
selection criteria for studies included, and data extraction etc.  In summary, a review of the literature 
was undertaken to assess the appropriateness of the EQ-5D in terms of classic psychometric criteria 
(WP1.1); where the EQ-5D was not considered appropriate, additional searches were undertaken to 
identify alternative measures (WP1.2); and finally, existing health technology appriasials were 
reviewed and data requirements were compared with variables currently collected in the IBD audit 
(WP1.3).   
3.1 Psychometric properties (WP1.1) 
Assessments reported in the included studies were categorised according to the following 
definitions: 
Acceptability 
Data relating to how acceptable the measure was to the person completing it, expressed as the 
proportion of completed surveys, or the proportion of missing data. 
Reliability 
There are two main definitions for reliability, a) the degree to which a measure reproduces the same 
results in an unchanged population and b) the degree to which a measure reproduces the same 
results when completed by different assessors (e.g. patient and proxy report). In both cases, 
reliability can be assessed by re-testing, and calculating the correlations or difference between tests. 
In case a) the comparison may be between the same populations separated by time, where no 
change in health state was observed (as compared to using an alternative condition specific or 
generic measure). In case b) the measure may be completed by multiple people (proxies) on the 
ƉĂƚŝĞŶƚ ?Ɛ ďĞŚĂůĨ ĂŶĚ ƚŚĞŝƌ ƌĞƐƉŽŶƐĞƐ ĐŽŵƉĂƌĞĚ ǁŝƚŚ ƚŚŽƐĞ ŽĨ ƚŚĞ ƉĂƚŝĞŶƚ ? tŚĞƌĞ ƚŚĞ ŽƵtcome 
measure is specifically designed for self-report by patients, this test of reliability may be expected to 
produce less agreement.  
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Construct validity 
This is an assessment of how well an instrument measures what it intends to measure. Two main 
definitions are used in this review.  
a) Known group validity, where estimates for groups that are known to differ in a concept of interest
are compared either qualitatively or statistically. The known groups may be defined using other 
measures, according to clinical categorisation.  
b) Convergent validity assesses the extent to which a measure correlates with other measures of the
same or similar concepts. Correlation coefficients were considered low if <0.3, moderate if between 
0.3 and 0.5, and strong when >0.5.  
Responsiveness 
a) Change over time. This is an assessment of whether measurements using the instrument can
detect a change over time, where a change is expected. This may be before and after an 
intervention, or through progression of a disease. Evidence was considered to be good where a t-
test was significant, though weaker evidence to support responsiveness was considered where there 
was a change in the expected direction, but was not statistically significant or not tested. Effect size 
(ES) and standardised response mean (SRM) were also acceptable assessments of responsiveness.  
b) Ceiling and floor effects were also considered to be indicators of responsiveness. Assessments of
ceiling effects include the proportion of patients who score full health within a group of patients 
with known health detriments. A ceiling or floor effect can affect the sensitivity of the measure in 
detecting changes over time in patients at the extremes of the measure (for example those with 
severe disease activity and those with just minor symptoms of the condition). 
3.2 Alternative measures (WP1.2) 
As the IBD audit includes paediatrics and the EQ-5D is not designed for use in this population, 
alternative instruments were reviewed. This entailed both a review of existing guidelines, and a 
review of primary studies relating to the four prespecified paediatric measures (EQ-5D-Y, Child 
Health Utility 9D (CHU-9D), Health Utility Index mark 2 (HUI2), Paediatric quality of life inventory 
(PedsQL)(1-4)), as detailed in section 3.2, Appendix A.  
3.3 Evidence required for economic evaluations (WP1.3) 
The existing Health Technology Assessment (HTAs) were reviewed alongside the variables currently 
collected in the NCA to determine if clinical or PROM data routinely collected in the NCAs would 
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suffice to address questions of cost-effectiveness, and to identify any gaps in the evidence that 
would be required to compare providers, or the cost-effectiveness of interventions or policies. 
4. RESULTS FOR INFLAMMATORY BOWEL DISEASE
4.1 Evidence of appropriateness of EQ-5D in Inflammatory Bowel Disease (IBD) (WP1.1)
As no existing review was known to the authors (see Appendix A), and no relevant systematic review 
was identified by Longworth et al. 2014a, (5)a search was performed to identify primary studies 
reporting the results of a psychometric assessment of the EQ-5D in patients with IBD (specifically, 
CƌŽŚŶ ?ƐĚŝƐĞĂƐĞ ?CD) or ulcerative colitis (UC)).  The systematic review of primary studies is reported 
below.  All associated Tables are provided in the Appendix. 
4.1.1 Results of searches for primary psychometric studies in IBD 
Searches for primary studies identified 89 unique titles of potential relevance. 75 studies were 
excluded upon examination of their title and abstract. The full text of 14 titles was obtained, of 
which two met the criteria for inclusion in this review. The excluded articles are listed in Appendix B 
with reasons for exclusion.  
4.1.2 Studies included in the systematic review of primary studies for IBD 
Two studies assessed the psychometric properties of the EQ-5D in IBD.(22;23)  Both studies were 
performed in Germany and both recruited a mix of adult patients (N=152;(6) N=502(7)) with either 
CD (80.9%,(6) 53.8%(7)) or UC (19.1%,(6) 46.2%(7)).  Konig et al. used the van der Schulenburg 
(1998) German EQ-5D tariff (range: 0 W100) which is not comparable with the United Kingdom (UK) 
preference-based EQ-5D index.(8) Consequently only the results of the analyses involving the EQ-5D 
health dimensions (and not the EQ-5D index) are reported below.(6) Stark et al. used a more recent 
German EQ-5D tariff, and the standard UK EQ-5D tariff.(9;10) The results for analyses conducted on 
the EQ-5D health dimensions and UK EQ-5D index scores are reported below for this study.   
Stark et al. compared the EQ-5D data with the inflammatory bowel disease questionnaire (IBDQ 
ƌĂŶŐĞ P  ? ?  ?ǁŽƌƐƚ ? ƚŽ  ? ? ?  ?ďĞƐƚ ? ?ĂŶĚ ƚŚĞƌŽŚŶ ?ƐĚŝƐĞĂƐĞĂĐƚŝǀŝƚǇ ƐĐŽƌĞ  ?/ ƌĂŶŐĞ PƵŶďŽƵŶĚǁŝƚŚ
disease categories PA? ? ? ?ƋƵŝĞƐĐĞŶƚ ?AN ? ? ?ĂĐƚŝǀĞ ?AN ? ? ?ĞǆƚƌĞŵĞůǇƐĞǀĞƌĞ ? ?(11;12)  Stark et al. used the 
following sub-groups: CD (n=270) and UC (n=232); patients in remission (CD=57.1%, UC=62%) versus 
patients with active disease (CD=42.9%, UC=38%); patients who reported no change in health status 
over time (n=360) versus patients who reported a change in health status over time (worse health 
n=29, better health n=42) all sub-categorised by CD, UC, remission or active disease status.(7) Konig 
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et al. compared the EQ-5D with short form -36 (SF-36) health dimensions (physical functioning, role 
limitations, social functioning, pain, mental health; all range 0-100), the CDAI and the clinical activity 
index (CAI).(12;13)  The latter two instruments are validated clinical measures in IBD and were used 
to sub-group patients by severity of symptoms or disease activity and changes over time.(12;13)  
Konig et al. used the following sub-groups in their analyses: inpatients (n=31) versus outpatients 
(n=113); patients with active disease (n=58) versus patients in remission (n=94); patients who 
reported no change in health status over time (n=52).(6)  It should be noted that some of the sample 
sizes of the sub-groups were relatively small, and results from these comparisons may not be robust. 
The cohorts in the two studies were similar in terms of age at diagnosis  ?ĂůůǁĞƌĞĂĚƵůƚƐA? ? ?ǇĞĂƌƐ
old), duration of disease, number in remission and number with active disease (Table A2, Appendix). 
Small numbers of patients were missing from some analyses in both studies. 
4.1.3 Psychometric properties reported in the primary studies for IBD 
All evidence related to adults (A? ? ?ǇĞĂƌƐŽĨĂŐĞ ? ? 
Acceptability: Konig et al. examined the acceptability of the EQ-5D by assessing the proportion of 
missing responses and found it to be well accepted with less than 3.5% of EQ-5D responses missing 
(compared to 9% for the IBDQ)(Table A4, Appendix).(6)  Stark et al. did not assess acceptability as 
the sample analysed only included respondents who completed the EQ-5D (N=502).(7) 
Reliability: Both studies reported results for test/retest reliability for patients who reported no 
change in health status over time (Table A4, Appendix). The proportion of agreement in outpatients 
who reported no change (n=52/66) over an average period of 19.5 days ranged from 80.4% for the 
health dimension anxiety/discomfort (kappa=0.61, p-values not reported) to 100% for the health 
dimension self-care (kappa=1.0).(6)  Similar results were reported for sub-groups of patients (CD 
n=195, UC n=166) who reported no change at follow-up in the second study with substantial or 
almost perfect agreement for all five health dimensions (kappa>0.60, p-values not reported).(7)    
Construct validity (known group): When comparing the results for outpatients (n=120) and 
inpatients (n=31), there was no significant difference in responses for the health dimensions 
pain/discomfort (p=0.5994) or anxiety/depression (p=0.4394). Assuming outpatients would have a 
better health related quality of life (HRQoL) than inpatients this result is not as expected.  However, 
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the number of inpatients was small, possibly resulting in underpowering.(6) When comparing 
patients with UC who were in remission with those with active disease, the mean EQ-5D preference 
based scores and the responses for the health dimensions were significantly better for those in 
remission (p<0.001), with the exception of the responses for the dimension self-care (p=0.20).(7)  
Comparing sub-groups, the responses for all five health dimensions were significantly better for 
those in remission compared to those with active disease.  For example, 96.1% of patients in 
remission indicated they had no problem with mobility compared to 66.0% of patients with active 
disease, p<0.0001).(6)   
Construct validity (convergent):  Correlation between the EQ-5D preference-based index and the 
activity indices were good (Spearman rank: r=-0.75 for CDAI, r=-0.65 for CAI, p<0.0001) 
(Appendix).(7) Assessing the median responses on the SF-36 and IBDQ dimensions with the median 
responses on comparable EQ-5D health dimensions (for example physical functioning on the SF-36 
was compared with mobility on the EQ-5D, emotional functioning on the IBDQ was compared with 
anxiety/depression on the EQ-5D), with the exception of the EQ-5D dimension self-care, the results 
were ordered appropriately according to the responses on the EQ-5D dimensions and results were 
significantly different between the groups (p<0.0001) (Table A4, Appendix).(6)  Stark did not assess 
this property.(7) 
Responsiveness (change over time): When assessing responsiveness to change in health status over 
time (Table A5, Appendix), statistically significant changes in the expected direction were observed 
for the EQ-5D preference-based index (change in mean EQ-5D: -0.09, p<0.05 for worse health 
(n=26); 0.095, p<0.0001 for improved health (n=41)).(7) Stark et al. also performed a number of sub-
group analyses, including analysing patients with CD, UC, those with active disease, or those who 
were in remission separately. In these sub-group analyses, the direction of effect was as expected, 
but not all sub-group analyses were statistically significant. The results for all sub-groups who 
reported an improvement in health were statistically significant (except for the remission sub-group 
(n=19)), though again the small numbers may cause underpowering. Of the results for the sub-
groups who reported a deterioration in health, the analyses for patients in remission (n=9), and 
those with UC (n=16) were statistically significant (p<0.05). 
In those reporting an improvement in health, the direction of effect was as expected in all groups, 
but a strong effect (defined as SRM >0.8) was only seen in UC (n=20, SRM=0.83) and those in 
remission (n=19, SRM=1.10). Similarly, for those who reported a deterioration in health, all effect 
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sizes were in the expected direction, but only the results for patients in remission (n=9, SRM=-0.82) 
and those with UC (n=10, SRM=-0.84) showed a strong effect. 
Responsiveness (ceiling effect): Both studies assessed potential ceiling effects on the EQ-5D (Table 
A5, Appendix). Some evidence of a ceiling effect was reported with 19.4% and 30.1% of inpatients 
and outpatients respectively scoring no problems on any of the five health dimensions,(6) and 43% 
and 31% for patients with UC or CD respectively scoring full health on the EQ-5D preference-based 
index (EQ-5D=1).(7) These results indicate the EQ-5D may not be able to discriminate between 
different health states in patients with less severe disease or who are in remission, and may be less 
responsive to improvements over time in these groups. However, it was noted in both studies that 
the distribution of patients across disease severity was skewed towards those who were less 
severely affected by the conditions; for example the median IBDQ total score was 174 (observed 
range 66-224) in one study,(6) and just 0.4% and 2.2% of patients with CD and UC respectively were 
reported as having severe disease activity in the second study.(7) As such, the studies may be biased 
towards overestimating a ceiling effect in a routine NHS IBD population. 
4.1.4 Conclusion of appropriateness of EQ-5D in IBD  
The evidence base assessing the performance of the EQ-5D in IBD is currently small, with only two 
studies satisfying the inclusion criteria for this review and only one of these assessing EQ-5D UK tariff 
data.(7) All studies were in adults. The EQ-5D was well accepted with less than 3.5% of EQ-5D 
responses missing (compared to 9% for the IBDQ). Construct validity was generally good on all EQ-
5D health dimensions (except self-care in patients with UC) when assessed against the disease 
activity indices, and when discriminating between those with active disease and those in remission.  
Some problems were observed in the health dimensions pain/discomfort and anxiety/depression for 
outpatients relative to inpatients but the sample sizes were very small for some comparisons.  There 
was some evidence of the EQ-5D being a responsive measure in those with active disease (further 
away from full health) who reported a deterioration in health.  Lack of statistically significant results 
suggest there may be problems with the EQ- ? ?Ɛ ƌĞƐƉŽŶƐŝǀĞŶĞƐƐ ǁŚĞŶ ĚĞƚĞĐƚŝŶŐ ĐŚĂŶŐĞƐ ŝŶ ůĞƐƐ
severely ill patients and those in remission.  Small numbers of patients in the sub-group analyses 
used to assess responsiveness made it difficult to draw robust conclusions, however, ceiling effects 
were also observed.  Stark et al. did not include a representative proportion of severely ill patients, 
and the authors recommended that further studies are conducted in this group of patients.(7)   
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In conclusion, the evidence supporting the appropriateness of the EQ-5D in adults with IBD is good 
but limited and there is a lack of evidence relating to how appropriate the EQ-5D is for surgical 
health states (Table 1).  Evidence is required in paediatrics, and in patients with more severe disease, 
both of which are relevant for the IBD NCA population (see Section 3.2). 
4.2 Alternative measures in IBD (WP1.2) 
The IBD NCA includes paediatrics as well as adults and the EQ-5D adult version is not recommended 
for use in paediatrics.  There is a youth version of the EQ-5D called the EQ-5D-Y, which is based on a 
minor modification of the wording of the items in the original measure.  However, this is a relatively 
new version and is not widely used as yet. Consequently, searches were conducted to identify 
alternative measures for use in paediatrics and adults. This comprised a search for existing 
guidelines and recommendations (section 4.2.1) and a separate search for primary studies relating 
to EQ-5D-Y, CHU-9D, HUI2, and PedsQL (section 4.2.2).(1-4) 
4.2.1 Alternative measures for IBD 
Eleven documents were identified by the initial searches as described in Section 3 and Appendix A. 
Four documents were from the Royal College of Paediatrics and Child Health, describing various 
results from the IBD NCA reviewed below (Section 4.3), and thus were excluded from further 
analysis.(14-17) A further five documents related to irritable bowel syndrome and were 
excluded,(18-22) leaving two reports of relevance to this analysis.(23;24) One was a research 
guideline from the European Medicines Agency (EMA), produced by an expert panel with a 
stakeholder consultation period.(23)   The report related to CD, and contained a very brief section on 
paediatrics where the paediatric version of the CDAI (the PCDAI) was recommended as a 
measurement of efficacy.(23)  The final and most recent report (2014) provided a synopsis of the 
literature available for a particular pharmaceutical intervention in severe, active UC.  This document 
listed several clinical and HRQoL measures used in randomised controlled trials (RCTs) in adults (no 
paediatric evidence) with UC but no attempt was made to evaluate these.(24) 
In addition to the reports described in the previous paragraph, evidence presented in three 
manuscripts known to the authors is worthy of consideration.(25-27) While these sources are of 
relevance, it should be noted that they were not found through a systematic search process, and 
consequently other relevant evidence may not have been identified.   
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The first source of evidence is a systematic literature review which compared the contents of IBD 
specific PROMs relative to the World Health Organization's International Classification of 
Functioning, Disability and Health (ICF).(26)  Four databases (Medline®, EMBASE, PsycINFO, CINAHL 
and CENTRAL by MC) were searched (terms:  ‘ŽůŝƚŝƐ ? hůĐĞƌĂƚŝǀĞ ? ?  ‘ƌŽŚŶ ŝƐĞĂƐĞ ? ?  ‘/ŶĨůĂŵŵĂƚŽƌǇ
ŽǁĞůŝƐĞĂƐĞ ? ŝŶƚŝƚůĞĂŶĚĂďƐƚƌĂĐƚ, and MESH terms (if available)).  Articles were limited to those 
written in English which were published between 1999 and 2009.  46 studies were selected from the 
initial hits identified (n=9728).  These studies used eight IBD-specific PROMs including: Cleveland 
Global Quality of Life (Faszio Score) (CGQL),(28) Inflammatory Bowel Disease Quality of Life 
Questionnaire (IBDQOL),(29) Inflammatory bowel disease questionnaire (IBDQ-32),(30) 
Inflammatory bowel disease stress index (IBDSI),(31) Inflammatory Bowel Disease Questionnaire - 
short form (IBDQ-9),(32;33) Rating Form of IBD Patient Concerns (RFIPC),(34) Short Inflammatory 
Bowel Disease Questionnaire (SIBDQ),(35)and Work Productivity and Activity Impairment: Crohn's 
Disease (WPAI: CD).(36) The IBDQ-32,(30) was used in 60% (36/46) of the studies with the next most 
common being IBDQOL (6/46), followed by the RFIPC (5/46) and SIBDQ (5/46).  The measures were 
not reviewed in any detail other than their ability to capture ICF and they cannot currently be used 
to generate utility values. 
The second source of evidence is a conference abstract which presented an exploratory analysis 
examining whether items on the CDAI (pain, stool frequency, general well-being, recorded over a 7 
day period) diary card (recorded over 7 days) could be adapted to be used as a PROM in adults with 
ƌŽŚŶ ?Ɛ ĚŝƐĞĂƐĞ ?(25)  Two potential measures were explored: the Patient Reported Outcome-2 
(PRO2) score (range: 0-35) which used abdominal pain and stool frequency; and the Patient 
Reported Outcome-3 (PRO3) score (range: 0-50) which used abdominal pain, stool frequency and 
general well-being.  While only summary results are currently in the public domain, these are 
promising.  Estimates of effects were similar in the PROMs and the full CDAI scores (range: 0-400) 
across various sub-groups in an RCT.  The PRO3 appeared to have a slightly higher correlation with 
the end of study CDAI score (r=0.89 vs. r=0.76), and change in scores (r=0.71 vs. 0.51) than the PRO2. 
The third source of evidence was produced by the UK IBD Standards Group in 2013, and draws on 
data collected in the first three rounds of the UK IBD Audit, the National Royal College of Nursing 
Inflammatory Bowel Disease Nursing Audit and other national reports funded by government and 
charities.  This report provides some information relating to the newly formed UK IBD register (June 
2013) which is a repository of anonymised data from adult and paediatric patients with IBD.(37)  
These data are to be used for prospective audit and research purposes and it is believed the register 
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will be linked to the current IBD audit.  The priorities identified by the authors ŝŶĐůƵĚĞĚ P ‘ĞǀĞůŽƉŝŶŐ
agreed clinical and patient-reported outcome measures that will support ongoing monitoring of the 
quality, safety and cost-ĞĨĨĞĐƚŝǀĞŶĞƐƐ ŽĨ / ƐĞƌǀŝĐĞƐ ? ‘ The authors also referred to two PROMs-
related projects (discussed below) which were ongoing at the time of publication.(38;39)   
The first project involved the IBD-Control
©
, a PROM which was developed to capture outcome data 
in adult patients with IBD in a busy clinical setting.(38)  The objective was to inform face-to-face 
consultations, or telephone/virtual clinics.  Using a recall period of the previous two weeks, and 13 
questions, the measure captures treatment concerns and the physical, emotional and social impact 
of IBD.  Responses to eight of the questions provide an overall summary score (IBD-Control-8 range: 
0-16 where 0=worse control). The measure has been validated, using the EQ-5D, the IBD-Control, 
quality of life questionnaire (UK-IBD-Q), and several clinical measures, in a study including adults 
with CD (n=160) and UC (n=139).  Bodger et al. concluded the IBD-Control was a rapid (mean 
completion time =1 min 15 secs), reliable (Intraclass correlation coefficient (ICC) test-retest using 2 
ǁĞĞŬƌĞƉĞĂƚA? ? ? ? ? ? ?ǀĂůŝĚ ?ŵŽĚĞƌĂƚĞƚŽƐƚƌŽŶŐĐŽƌƌĞůĂƚŝŽŶƐǁŝƚŚh<-IBD-Q and EQ-5D (r =0.52-0.86), 
analysis of variance (ANOVA) for detecting difference in remission, mild, moderate or severe disease 
(p<0.001)), and sensitive (ES: 0.76-1.44) measure.(38)  
The second project involved the ƌŽŚŶ ?Ɛ>ŝĨĞ /ŵƉĂĐƚYƵĞƐƚŝŽŶŶĂŝƌĞ  ?>/Y ?, designed to capture the 
ŝŵƉĂĐƚŽĨƌŽŚŶ ?ƐĚŝƐĞĂƐĞĨƌŽŵƚŚĞƉĂƚŝĞŶƚ ?ƐƉĞƌƐƉĞĐƚŝǀĞ ?ĂŶĚ the first PROM specifically designed 
for adult patients with CD.(39)  The CLIQ consists of 27 items relating to quality of life and 9 relating 
to activity limitations; producing two corresponding unidimensional scales (range: 0-25 with 25 
being the most severely affected).  In a validation survey (n=273) using the Nottingham Health 
Profile (NHP) measure as a comparator, internal consistency was reported to be good and both CLIQ 
scales were shown to distinguish between self-reported severity of CD, general-health and work 
status.  While both CLIQ scales correlated with the NHP (p<0.01), the relationship was strongest 
between the CLIQ QoL and the NHP Emotional reaction scores (r=0.80); and the CLIQ activity 
limitation and the NHP physical mobility scores (r=0.65). 
4.2.2 Measures for paediatrics with IBD 
As the results of the review above (Section 4.2.1), and the review performed under WP1.1 (Section 
3.1) did not provide conclusive evidence to support the use of a particular measure in paediatrics, an 
additional search was conducted with the aim of identifying any literature describing the 
psychometric properties of the four pre-specified preference-based measures in IBD. 
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Results of searches: The searches identified 49 unique references.  Full papers of 10 studies 
identified as being potentially relevant when the abstract and title were assessed against the 
inclusion criteria were obtained.  An additional manuscript was identified from the references lists of 
these 10 papers,(40)  Of the 11 papers, one did not present the psychometric properties of any 
measure,(41) and two did not report sufficient details for the IBD subgroup (Table A6, 
Appendix).(42;43)  A total of eight articles, representing seven studies, satisfied the inclusion criteria 
and were included in this review.(40;44-50) 
Results of review:  Across the seven included studies, the psychometric properties of both IBD-
specific measures and generic measures were reported (Appendix).  No studies were identified 
which presented evidence relating to the use of the CHU-9D, HUI2, or EQ5D-Y in paediatrics with 
IBD. 
Abdovic et al. assessed the reliability and validity of the IMPACT-III questionnaire in Croatian children 
with IBD.(44)  While primarily examining the translated version of the IMPACT-III questionnaire, as 
ƚŚĞ ĐŽŵƉĂƌĂƚŽƌ ǁĂƐ ƚŚĞ ŐĞŶĞƌŝĐ WĞĚƐY> ? ŵĞĂƐƵƌĞ ? ƚŚĞ ƌĞƐƵůƚƐ ĂƌĞ ƉŽƚĞŶƚŝĂůůǇ ƌĞůĞǀĂŶƚ ĨŽƌ ŽƚŚĞƌ
settings.  Duffy 2011, described several HRQoL measures used in children with either juvenile 
idiopathic arthritis or IBD but provided limited information on the psychometric properties of the 
instruments.(45)   Marcus et al. examined fatigue and HRQoL (IMPACT-III, PedsQL
TM
) in children 
(aged 10-17 years) with a clinical diagnosis of IBD (CD=52, UC=13) compared with healthy controls 
(n=157).(46)  Perrin et al. evaluated the IMPACT Questionnaire against the PedsQL v4 in children 
(aged 8-18 years) with either UC (n=59) or CD (n=161), using the WĂĞĚŝĂƚƌŝĐƌŽŚŶ ?ƐĚŝƐĞĂƐĞĂĐƚŝǀŝƚǇ
index (PCDAI) to categorise severity.(47)  Upton assessed the UK translation of the PedsQL
TM
 v4 in a 
relatively large sample of children (n=1,399) with IBD and their parents (n=970).(48)  Ogden used a 
sample of children with IBD (n=97) to assess the psychometric properties of the IMPACT-III (UK), 
using the Child Health Questionnaire (CHQ) as the comparator.(40)  Finally, Varni et al. and Lane et 
al. (conference abstract only) presented results from the same study which described a de-novo 
gastrointestinal (GI) module for the PedsQL.  The module was compared with the PedsQL
TM
 v4 and 
was assessed in children (aged 3-18 years) with either CD (n=192) or UC (n=67).(49;50)   
No studies were identified in this population for the three paediatric generic preference-based 
measures (EQ-5D-Y, CHU-9D, HUI2).  A brief synopsis of the measures used and the psychometric 
properties of the measures reported within the seven studies are provided below, sub-grouped by 
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IBD-specific measures and generic HRQoL measures.  It should be noted that not all these measures 
are PROMs, and the clinician reported measures (generally used as a comparator for the HRQoL 
measures, or to define severity-based subgroups) are included for completion only. 
IBD-specific measures used in paediatrics with IBD 
Two IBD-specific measures that had been used in paediatrics with IBD were identified: the IMPACT 
questionnaire (available as versions I, II and III)(51-53) and the WĂĞĚŝĂƚƌŝĐ ƌŽŚŶ ?Ɛ ŝƐĞĂƐĞ ĐƚŝǀŝƚǇ
Index (PCDAI).(54) 
The IMPACT Questionnaire is a self-report measure developed for children (9 years and over) with 
IBD.(51;52)  The IMPACT-III version (an update of versions I and II) includes 35 questions covering six 
domains: bowel symptoms, systemic symptoms, social functioning, body image, 
treatment/interventions, and emotional functioning. The responses (each question has a five-point 
Likert scale response) are used to generate a total score (range 35 to 175), where higher values 
indicate a better quality of life.(45)  The IMPACT-III does not have a preference-based tariff and thus 
cannot be used to generate quality adjusted life years (QALYs) in economic evalutions without a 
validated relationship with a preference-based measure. Three studies included in this review 
reported data relating to the psychometric properties of IMPACT III.(40;44;45) Two studies included 
in this review reported data relating to the psychometric properties of IMPACT II but as this version 
is superceded by IMPACT III, the evidence is not reported here.(45;47) 
Acceptability: Abdovic reported acceptability was good with all patients (n=104) completing the 
IMPACT-III questionnaire compared to 94% of patients completing the PedsQL
TM
 v4.(44) Similarly, 
93/94 of children in the Ogden study believed the questions were easy to understand, and 87/94 
indicated, if requested, they would complete the IMPACT-III again.(40) 
Reliability:  Test-retest reliability (n=50) over a period of 4-8 weeks was reported to be good in the 
validation study (ICC between 0.66 and 0.84).(40) Internal reliability was reported to be very good 
(ƌŽŶďĂĐŚ ?ƐɲA? ? ? ? ? W0.88) for all domains in the validation study.(40) Internal consistency was high 
for the IMPACT-/// ƚŽƚĂů ƐĐŽƌĞ  ?ƌŽŶďĂĐŚ ?Ɛ ɲA? ? ? ? ? ? ĂŶĚ ǁith the exception of the treatment 
interventions sub-score (ƌŽŶďĂĐŚ ?Ɛ ɲ=0.33) all reliability coefficients were greater than 0.61 in a 
second study.(44) 
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Construct validity (known group): Significant differences across sub-groups categorised by severity 
(severe vs. moderate vs. inactive/mild symptoms) groups were observed for the embarrassment 
scale (63.7
*
 vs. 81.0 vs. 81.2, 
*
p<0.05), symptom scale (45.0
**
 vs. 64.2
*
 vs. 80.6, 
*
p<0.05, 
**
p<0.01), 
and the energy scale (46.4
*
 vs. 62.1
*
 vs. 77.7, 
*
p<0.05) in the validation study.(40)  While the 
IMPACT-III was shown to distinguish between those with active (n=45) and inactive (n=59) disease, 
the difference in mean scores when comparing moderate/severe activity (n=8) with mild activity 
(n=37) was not statistically significant (p>0.05) in a second study.(44) However, these sample sizes 
were extremely small. 
Construct validity (convergent): Using comparable domains on the IMPACT-III and the Child Health 
Questionnaire (CHQ), convergent validity was confirmed in the validation study with significant 
correlations (p<0.001) for all comparisons presented (e.g. energy compared with physical function, 
r=0.63, p<0.001).(40) With the exception of the associations between the IMPACT-III domain worry 
about stool and the PedsQL
TM
 ĞŵŽƚŝŽŶĂů ?ƐŽĐŝĂů ?ƉƐǇĐŚŽƐŽĐŝĂůĂŶĚƐĐŚŽŽůƐƵďƐĐĂůĞƐ ?ƌA? ? ? ? ? ?ĨŽƌĂůů ? ?
the correlations between the IMPACT-III and PedsQL domains were moderate to strong (r>0.4, 
p<0.001 for all).(44)  Strong relationships were reported between the total IMPACT-III scores and 
self-reported PedsQL
TM
 v4 scores (r=0.74, p<0.001), the PedsQL
TM
 fatigue scores (r=0.63, p<0.001), 
and the PCDAI scores (r=-0.52, p<0.0001).(46)  
dŚĞ WĂĞĚŝĂƚƌŝĐ ƌŽŚŶ ?Ɛ ŝƐĞĂƐĞ ĐƚŝǀŝƚǇ /ŶĚex (PCDAI)(54) used in Marcus(46) and Perrin(47).  The 
PCDAI is a clinician-completed measure used to determine the severity of the condition which uses a 
combination of clinical history, physical examination and laboratory results.  Possible scores range 
from 0 to 100, with larger scores indicating more disease activity. It has been reported to have good 
reliability, and to be responsive to change in paediatric patients with CD.(55;56)  The PCDAI cannot 
be used as a PROM at the moment.  While it is possible that the exploratory research exploring the 
feasability of adapting items in the adult CDAI to use as a PROM (PRO2 or PRO3) may be exended to 
the paediatric version (see Section 4.2.1), this is unlikely to happen in the near future.  In addition, 
the PCDAI cannot be used to generate utility scores without a validated relationship with a 
preference-based measure. 
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Evidence on generic- measures used in paediatrics with IBD 
Amongst the included studies, data relating to the psychometric properties of three generic 
measures (with three variations of one measure) were identified. These were: cŚŝůĚƌĞŶ ?Ɛdepression 
inventory  W short-form (CDI); child health questionnaire (CHQ); the paediatric quality of life 
inventory (PedsQL); The PedsQL Multidimensional Fatigue Scale (PedsQL MFS); and the PedsQL 
gastrointestinal (PedsQL GI) module.  
ŚŝůĚƌĞŶ ?ƐĞƉƌĞƐƐŝŽŶ/ŶǀĞŶƚŽƌǇ ?short-form (CDI)(57) was used in Marcus et al., and referred to in 
Duffy 2011.(45;46)  The CDI is a self-report screening measure for symptoms of depression in 
children aged 7-17 years.  Items relate to thoughts and behaviours over the previous two weeks and 
total scores range from 36-100 with scores greater than 63 being indicative of clinically significant 
symptoms of depression.  There was no significant difference in mean scores (44.8 vs. 43.9) when 
comparing patients with IBD (n=70) and healthy controls (n=157), or in the percentage of 
respondents with clinically significant depressive symptoms (1.4% vs. 1.3%).  However, an inverse 
relationship was shown between the CDI short-form scores and the PedsQL MFS, indicating a direct 
relationship between fatigue and symptoms of depression.(46)  The CDI does not measure all 
aspects of HRQoL and cannot be used to generate QALYs in economic evalutions. 
Child Health Questionnaire (CHQ)(58) used in Ogden 
KƌŝŐŝŶĂůůǇĚĞƐŝŐŶĞĚďǇ>ĂŶĚŐƌĂĨŝŶƚŚĞ ? ? ? ? ?Ɛ ?ƚŚĞ,YŝƐĚĞƐŝŐŶĞĚƚŽŵĞĂƐƵƌĞǁĞůůďĞŝŶŐ ?ĨƵŶĐƚŝŽŶĂů
health status, and health outcomes in children (4-19 years) and is a widely used and accepted 
measure. The parent/proxy (CHQ-PF50)(59) is the most widely used version while the Child Health 
Questionnaire  W child form 87 (CHQ-CF87) is completed by adolescents (age 10-19 years).(60) The 
questionnaire includes 87 items covering the following domains: behaviour, bodily pain, general 
health, mental health, physical functioning, parent impact-time, parent impact-emotional, role-
ĞŵŽƚŝŽŶĂůA?ďĞŚĂǀŝŽƵƌĂů ? ƌŽůĞ-physical, and self-esteem.  There are two overall summary scores: 
physical and psychosocial (range 0-100 with 100 being better health).  This measure was used as the 
comparator in the study by Ogden et al. when assessing the psychometric properties of the IMPACT-
III (UK), as discussed above.  As the literature searches were not designed to identify evidence for 
this measure, and no evidence was found on the psychometric properties, additional searches and a 
review of all evidence on the measure used in IBD would be required before it could be 
recommended for inclusion in the NCA. 
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The Paediatric Quality of Life Inventory (PedsQL)(49) 
Data relating to the psychometric properties of PedsQL were reported in Abdovic et al., Duffy et al., 
Marcus et al., Perrin et al, and Upton et al.  The PedsQL, a generic measure of HRQoL, has been 
reported as being one of the most thoroughly developed measures available for paediatrics.(60)  It 
takes 4 minutes to complete and is either self-completed (5-18 years), or completed by a 
parent/caregiver (2-18 years), and comes in 3 forms designed for the patients age (5-7, 8-12, 13-18 
years).  The measure (version 4) covers 23 items describing four domains: emotional (5 items), social 
(5 items), physical (8 items), and school (5 items).  Items are answered on a five-point Likert scale 
(0A? ‘ ‘ŶĞǀĞƌĂƉƌŽďůĞŵ ? ?ƚŽ ?A? ‘ ‘ĂůŵŽƐƚĂůǁĂǇƐĂƉƌŽďůĞŵ ? ? ? ?The scores from these are used to derive 
summary scores in physical health (8 items) and psychosocial health (15 items), and an overall total 
score.  These are all standardised (0-100) where higher scores indicate better HRQoL.   The PedsQL 
does not have a preference-based tariff which could be used to generate QALYs in economic 
evaluations, and the main researcher and originator of the measure has no immediate plans to 
conduct research in this area.(49) [personal communication, Varni June 2014] 
Acceptability: Acceptance was very good in one study (CD=74, UC=30) with just 5.8% (6/104) of 
ĐŚŝůĚƌĞŶ  ?ĂŐĞĚ A? ? ǇĞĂƌƐ ? ŶŽƚ ĐŽŵƉůĞƚŝŶŐ ƚŚĞ WĞĚƐY> ǀ ? ĐŽŵƉĂƌĞĚ ƚŽ  ? ? ?A? ǁŚŽ ĐŽŵƉůĞƚĞĚ ƚŚĞ
IMPACT III questionnaire.(44) 
Reliability: /ŶƚĞƌŶĂů ĐŽŶƐŝƐƚĞŶĐǇ ǁĂƐ ŐŽŽĚ ĨŽƌ ƚŚĞ WĞĚƐY> ƚŽƚĂů ƐĐŽƌĞ  ?ĐƌŽŶďĂĐŚ ?Ɛ ɲA? ? ? ? ? ?(44) 
ɲA? ? ? ? ?(46), and summary scoreƐ  ?ɲA? ? ? ? ?(44) ?ɲA? ? ? ? ?.(46)  Internal reliability of the UK version of 
the PedsQL sub-scales was reported to exceed 0.70 for self-report (total n=1,399, IBD n=76) and 
proxy-reports.(total n=970, IBD n=87).(48) 
Construct validity (convergent): Comparing domains on the PedsQL with similar domains on the 
/DWd///ƋƵĞƐƚŝŽŶŶĂŝƌĞ ?ƚŚĞĐŽƌƌĞůĂƚŝŽŶƐǁĞƌĞƐƚƌŽŶŐ ?ƌA? ? ? ? ?ƉAM ? ? ? ? ? ?ŽƌŵŽĚĞƌĂƚĞ ?ƌA? ? ? ? ?ĨŽƌƚŚĞ
majority of comparisons.(44)  Weak correlations included: PedsQL school vs. IMPACT III concerns 
(r=0.269, p<0.01), PedsQL school vs. IMPACT III worry about stool (r=0.286, p<0.01), PedsQL
TM
 
emotional vs. IMPACT III worry about stool (r=0.262, p<0.01), PedsQL social vs. IMPACT III worry 
about stool (r=0.206, p<0.042).(44)  The PedsQL
TM
 total and subscales were also correlated with IBD 
specific factors on the Impact questionnaire (n=220), namely the well-being symptoms (r>0.52, 
p<0.001), and the total scale score (r>0.54, p<0.001).  The relationship was less strong (but 
significant, p<0.001) for the Impact questionnaire factors: emotiŽŶĂů ĨƵŶĐƚŝŽŶŝŶŐ  ? ? ? ? ?A?ƌA? ? ? ? ? ? ?
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ƐŽĐŝĂů ŝŶƚĞƌĂĐƚŝŽŶƐ  ? ? ? ? ?A?ƌA? ? ? ? ? ? ?ĂŶĚďŽĚǇ ŝŵĂŐĞ  ? ? ? ? ?A?ƌA? ?     (47) The PedsQL was also able to 
detect CD activity, as evidenced by the relationships with the PCDAI scores (total score: r=0.52 
p<0.0001; physical health: r=0.47 p<0.001); psychosocial health: r=0.51 p<0.0001; emotional 
functioning: r=0.46 p<0.001; school functioning: r=0.53 p<0.0001).(46) 
Construct validity (known group): The total PedsQL score was statistically significantly lower in 
patients with IBD (n=70), compared with healthy controls (n=157) (76.69 vs. 85.93, p<0.0001) and 
the ESs for the PedsQL 4.0 dimensions were reported to range from small (emotional functioning, 
ES=0.32; social functioning, ES=0.30) to large (total score, ES=0.89; physical health, ES=1.50; school 
functioning, ES=1.13).(45;46)  Similarly, the mean scores on the PedsQL total score, and the sub-
scales were lower in children with IBD (n=76) than in healthy controls (n=1032) for both self-report 
and proxy-report.(48)  With the exception of the self-report social functioning scale, all differences 
were statistically significant (p<0.05).(48) 
The PedsQL Multidimensional Fatigue Scale,(51) was used in Marcus et al., and referred to in Duffy 
et al.(45;46) 
The PedsQL MFS was designed to measure the perception of fatigue in children, and has been 
validated in paediatric patients with cancer and rheumatological diseases.(51)  With 18 items in 
total, it can be completed in less than 5 minutes, has self-report and parent-proxy versions (8-12 
years), plus an adolescent version (13-18 years).  The measure describes three fatigue domains 
including general (6 items), sleep/rest (6 items) and cognitive (6 items). The scores are transformed 
onto a 0-100 scale with higher scores indicating less fatigue.  Two of the studies identified 
report some psychometric properties of the PedsQL MFS in paediatrics with IB.(45;46)  
Comparing paediatrics with IBD (n=70) against healthy controls (n=157), the mean scores on the 
PedsQL Total score and three individual domains were lower in the IBD subgroup, and ESs ranged 
from 0.35 for cognitive function to 0.84 for general fatigue in the self-report data, and from 
0.72 for cognitive fatigue to 1.96 for general fatigue in the proxy-report scores.(46)  A direct 
relationship was reported between the total PedsQL 4.0 scores and the MFS (r=0.80, p<0.001).(46)   
There was also an inverse relationship between age and total MFS (r=-0.16, p=0.02), and a 
direct relationship was also reported between disease activity (measured using the PCDAI) and 
fatigue (range: r-0.40 to -0.48, p<0.01 for all).(46)  Although described here as it is used as a 
comparator in two of the studies in this review, the PedsQL MFS is not considered a candidate 
measure for inclusion in the NCA as it does not capture all aspects of HRQoL associated with IBD.   
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The PedsQL GI module used in Varni 2014 
There are several disease-specific modules of the PedsQL (for asthma, arthritis, cancer, cardiac 
disease, diabetes) which are designed to be used in conjunction with the core modules.  A recent 
publication provides initial results from a module designed for use in gastrointestinal (GI) conditions 
including IBD (CD and UC).  In development since 2008, this module has both parent-proxy (ages 2-4, 
5-7, 8-12, 13-18 years) and self-report versions (ages 5-7, 8-12, 13-18 years).  The module includes 
74 items describing 24 different scales relating to GI-specific symptoms: stomach pain and hurt (6 
items), stomach discomfort when eating (5 items), food and drink limits (6 items), trouble 
swallowing (3 items), heart burn and reflux (4 items), nausea and vomiting (4 items), gas and 
bloating (7 items), constipation (14 items), blood in poop (2 items), diarrhoea (7 items), worry about 
going poop (5 items), worry about stomach aches (2 items), medicines (4 items), and communication 
(5 items).(49)  As with the core modules, the scales are transformed onto 0-100 scale with higher 
scores indicating fewer problems and less severe symptoms.(49)  This measure is considered to be a 
candidate measure for the NCA when used in conjunction with the core PedsQL measure. 
A relatively large sample (n=584 children aged 5 W18 years, n=682 parents of children aged 2 W18 
years) of patients with either functional gastrointestinal disorders (FGIDs) or organic gastrointestinal 
diseases (including CD and UC) were used to assess the measurement properties of the PedsQL GI 
module.   
Acceptability: The module was well accepted with just 1.69% and 1.84% of item responses missing 
on the child self-report and parent proxy-reports respectively. 
Reliability: The ICC statistics between the self-report and parent proxy-report showed agreement for 
the vast majority of PedsQL GI scales, with exceptions being communication (ICC=0.37) and trouble 
swallowing (ICC=0.49).  Test-retest reliability was not tested. 
Construct validity (known group): The tests for known group validity (subgrouped by seven GI 
disorders with CD=192 and UC=65) showed the expected differences in mean scores (p<0.001) for 
both the child self report and the parent proxy-report, however, the sample sizes for the subgroups 
were extremely small in some cases. 
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Responsiveness: Although there was no evidence of floor effects, ceiling effects (less GI symptoms) 
were observed on a number of the individual scales (e.g. >60% scored the ŚŝŐŚĞƐƚǀĂůƵĞĨŽƌ ‘ďůŽŽĚŝŶ
ƉŽŽƉ ? ĂŶĚ  ‘ƚƌŽƵďůĞ ƐǁĂůůŽǁŝŶŐ ? ?, which may infer insensitivity to improvement in paediatrics with 
less severe symptoms.  Responsiveness to changes over time was not tested. 
Summary and conclusion of review of literature on paediatrics with IBD 
While primary research in this area appears to be growing with evidence of development of several 
PROMs targeted at paediatrics with IBD, the evidence identified which could be used to compare 
PROMs in this population was limited.  The searches, although limited in scope due to the time 
constraints of the project, did not identify any evidence which could be used to generate QALYs 
directly from PROMs in this population.  The most likely target measures for inclusion in the IBD NCA 
are the IMPACT-III and the PedsQL
TM
 v4.  Based on the evidence reviewed, the target age group, and 
alternative responder versions, the PedsQL
TM
 is recommended over IMPACT-III measure.  However, 
research is required to generate an associated preference-based tariff for the PedsQL
TM
 (or a 
mapping function to one of the alternative preference-based generic measures) which could be used 
to generate utility values for use in cost-effectiveness evaluations.  
Table 1: Summary of evidence on PROMs for IBD 
Measure (N) Target Age 
(years) 
Target 
Responder 
Acceptability Reliability Construct 
(KGV; 
Convergent) 
Responsiveness  
(Change over time; 
Ceiling effects) 
Adults 
EQ-5D (2) - - Good Good Good; Good Mixed; Mixed 
Acceptable but requires additional validation (n studies =2) particularly in patients with severe IBD and 
those undergoing surgical procedures.  Is not appropriate for paediatrics with IBD. 
PRO2, PRO3 (1) - - Very limited evidence available (n studies =1) 
Acceptable but requires additional validation and is only suitable for adults with CD (not for UC). 
Paediatrics 
IMPACT-III (3) A䠃? SR Good Good Mixed; Good No evidence 
Acceptable but requires additional validation (n studies = 3) and cannot be used to generate QALYs 
PedsQL (5) 2-18 SR;PR Good Good Good No evidence 
Acceptable (n studies = 5) but cannot be used to generate QALYs 
PedsQL GI 
module (1) 
  Good Good Good; No 
evidence 
No evidence; poor 
Acceptable, but very limited evidence (n studies = 1), would need to be used as an adjunct to the 
PedsQL core measure, and cannot be used to generate QALYs 
KGV = known group validity; CE=ceiling effect; N = number, SR=self-report, PR=Parent/carer-report 
EEPRU NCA Appendix C: IŶĨůĂŵŵĂƚŽƌǇ Bowel 
Disease Page 24 
4.3 Evidence for economic evaluations in IBD (WP1.3) 
4.3.1 Cost-effectiveness modelling approach used in recent HTAs in IBD 
Three technology appraisals (TAs) relating to IBD were identified from the searches.  One was 
superseded by a more recent publication,(61) leaving one multiple technology assessment 
(MTA),(62) and one single technology assessment (STA) (Table 2).(63)  The MTA compared several 
pharmaceutical interventions for the treatment of moderate to severe CD or fistulising CD in both 
adult and paediatric populations.(62)  The STA compared surgery (colectomy) with rescue therapy 
(standard care or alternative pharmaceutical interventions) for avoidance or delay of surgery and 
symptom free remission in hospitalised patients with acute exacerbation of UC.(61)  Both of these 
interventions are reflective of those provided to patients in the IBD NCA which gathers information 
from secondary care settings. 
The MTA used a Markov model with discrete health states defined by remission and surgery (Table 
2, Figure 1), with both clinical severity and remission informed by the CDAI (e.g. CDAI<150: quiescent 
disease or remission; 220<CDAI<300: moderately active disease; CDAI>300: severe disease).(64) The 
STA used an initial decision tree for the clinical trial data and extrapolated beyond the trial horizon 
using a Markov model.(61)  The clinical pathway was represented by discrete health states (e.g. 
achieved remission, failed treatment, colectomy, post-surgery complications etc).  Response was 
defined as: a clinic-activity score <10 on two consecutive days and a drop of at least three points 
(N.B. no additional details or reference was provided for the clinical-activity score).  Health state 
transitions for remission, relapse and post-surgical complications for both TAs were derived from 
RCT data.  Although adverse events for anti-TNF agents are a potential problem, these were not 
modelled explicitly, but were incorporated into withdrawal from the therapies.  Prevalence and 
changes in concomitant medications such as corticosteroids were sourced from clinical studies. 
Figure 1 provides a synopsis of the health states (orange framed boxes with uppercase text) and 
evidence (purple framed boxes with lower case text) used in the TA for CD. 
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Figure 1: Modelling approach used in CD HTA 
Both studies quality adjusted survival by assigning mean utility values to the discrete health states.  
For CD, published utility values elicited using time trade-off (TTO) methods were initially used.(65)  
The utilities used in the paediatric assessment, (62) and the surgical health states in both TAs were 
based on adult values and assumptions respectively due to the absence of more suitable data.  
Table 2: Summary of existing models used in IBD TAs 
Model method, clinical effect  Method used to model utilities  
MTA (TA187): Crohn's disease - infliximab (review) and adalimumab (review of TA40); 2010 
TAG Markov model 
Four discrete health states: remission
 ?
, relapse 
(severe: CDAI>300; moderate: 220<CDAI<300), 
surgery, post-surgery remission
 ?
, death 
Effectiveness: intervention specific rates for 
remission/relapse 
Source: RCTs used for clinical effect  
Utility: non-preference values obtained using TTO 
(65); mean values assigned to discrete HS 
Source: published literature (adults), assumptions 
AEs: not specifically modelled 
STA (TA163): Ulcerative colitis (acute exacerbations) - infliximab; 2008 
Decision tree followed by Markov model 
Four discrete health states: remission, active 
ulcerative colitis, surgical (colectomy) remission, 
surgical complications 
Effectiveness: individual intervention rates for 
colectomy, remission, surgical complications 
Source: RCTs used for clinical effect  
Utility: EQ-5D; mean values assigned to discrete HS 
Source: survey of patients with ulcerative colitis
AEs: assumed the disutility associated with post-
surgery complications were equivalent to the utility 
of active ulcerative colitis 
HS: health states; AE: Adverse Events; MTA: Multiple Technology Appraisal; STA: Single Technology 
Appraisal; TAG: Technology Appraisal Group; TA: Technology Appraisal; TTO: time trade-off; RCT: 
randomised controlled trial. 
 ?
remission: defined as a CDAI score <150 
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A subsequent critique of the economic model indicated that a published statistical model describing 
a continuous relationship between the CDAI and EQ-5D may be more appropriate than the discrete 
values applied to the individual health states.(62;66)  Figure 2 illustrates the potential continuous 
relationship between the proxy measure (CDAI) and the utility values (EQ-5D) required to generate 
QALYs.  The orange boxes represent the discrete health states used in the existing economic model 
while the blue (diamond marker) line and red (square marker) line show the changes in disease 
severity (measured using the CDAI) and utilities (measured using EQ-5D) over time respectively.  
Modelling a continuous relationship between utilities and a clinical measure of function or 
symptoms is now widely accepted as the most appropriate approach in chronic conditions 
characterised by periods of flares and remission.(67;68) 
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Figure 2: Alternative approach describing utilities by proxy measure (CDAI in CD) 
Legend: the orange boxes represent the discrete health states used in the CD cost-ĞĨĨĞĐƚŝǀĞŶĞƐƐŵŽĚĞů ?/ PƌŽŚŶ ?ƐĚŝƐĞĂƐĞĂĐƚŝǀŝƚǇŝŶĚĞǆ
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In summary, the following evidence would be required to compare providers or the cost-
effectiveness of interventions for IBD: 
x Condition severity (repeatedly measured over time using CDAI for CD, or CAI for UC)
x Surgical rates (type of intervention, success rate, post-surgical complication, length of stay)
x Pharmaceutical interventions (type of intervention, concomitant medications, remission
rates, relapse rates, adverse events)
x Utility values (collected alongside condition severity scores and surgical interventions)
x Death rates (IBD related, all cause)
The majority of this evidence would need to be linked through timings of collection. 
4.3.2 Fields collected in the IBD NCA 
The objective of the UK IBD NCA is to improve the quality and safety of care delivered in secondary 
care for patients (any age including paediatrics) with IBD throughout the UK.  The biennial audit 
collects information on processes and outcomes relating to both inpatient and outpatient services 
for IBD from each hospital participating in the audit.  Different levels of information are collected on 
each of three sub-categories: CD, UC, IBD unspecified, depending on the particular round of the 
audit.  For example, in the fourth round, the Inpatient, and Organisational audits were only 
completed for patients (up to a maximum of 50
1
 patients per hospital per year) with UC.  To be 
eligible for inclusion, the patients (of any age) had to have been admitted for treatment or surgery 
for UC, and had to have remained in hospital for longer than 24 hours.  Patients were not eligible for 
inclusion in the audit if the primary reason for admission was not treatment of UC, or they had a day 
case procedure (e.g. infusion, endoscopy or day surgery), or they were discharged within 24 hours of 
admission.  The clinical information is collected via three mandatory questionnaires (depending on 
audit round) completed by NHS staff: Inpatient audit, Organisational audit, and Biologic audit
2
.  
There is also a postal patient questionnaire of inpatient experience which includes individual patient 
unique identifiers and is completed following discharge by either the patient or their parent/carer 
(for paediatrics). 
1
 Multiple admissions for same person are treated as independent for the audit.  Hence a total maximum of 50 
entries may have less than 50 individual patients (multiple admissions linked via the system generated 
identifier) 
2
 As recommended by NICE, audit of the use of biologics (adalimumab, infliximab) is mandatory in all patients 
treated with these. 
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The Inpatient Care Audit is completed for individual patients and covers areas such as patient 
demographs, admission and mortality, the extent (or severity) of the condition/symptoms and any 
comorbidities, medical and surgical interventions, discharge arrangements, and any outpatient care 
prior to admission (Appendix).  The Organisational audit is completed once for the Trust/hospital 
and provides total numbers and organisation information in the following areas: patient and IBD 
staff demographs, patient experience and involvement in the IBD service, clinical quality (direct and 
extended IBD team, available access to specialists and diagnostic services, MDT processes, surgery, 
ŝŶƉĂƚŝĞŶƚ ĨĂĐŝůŝƚŝĞƐ ĂŶĚ ĐĂƌĞ ĞƚĐ ? ? ƉƌŽǀŝƐŝŽŶ ĂŶĚ ƐƵƉƉŽƌƚ ĨŽƌ ƉĂƚŝĞŶƚ ?Ɛ ĐŚŽŝĐĞ ŽĨ ĐĂƌĞ ? ƌĞƐĞĂƌĐŚ
involvement, and education provision and support (Appendix).  The Biologic audit is completed for 
each patient on anti-TNF therapy and contains information on: patient demographs, IBD disease 
details, initial anti-TNF therapy, current anti-TNF therapy including dose and continued use etc, 
treatment selection, reviews of treatment, any adverse reactions to the therapies, and a disease 
severity score (severe, moderate, mild).  The self-completed patient questionnaire, which includes 
the EQ-5D questionnaire, ŐĂƚŚĞƌƐ ŝŶĨŽƌŵĂƚŝŽŶ ŽŶ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ĞǆƉĞƌŝĞŶĐĞ ŽĨ ƚŚĞ ŚĞĂůƚŚĐĂƌĞ
services provided by the hospital and background information such as the reason for hospital 
admittance (elective, scheduled), the type of ward(s) they stayed on, toiletry facilities, hygiene, 
dietary requirements and standard of food received, the clinicians and nurses involved in providing 
care, their personal care and treatments, levels of pain, operations and procedures, and information 
on medications provided during hospitalisation and on discharge (Appendix).  
4.3.3 Comparing fields in IBD NCA with variables used in existing HTAs 
Based on the existing HTA models, the key clinical information required to inform a standard 
economic evaluation comparing interventions (either anti-TNF agents, or surgical procedures) in IBD 
in the secondary care setting would be: condition severity, therapy regimens, the associated 
remission, relapse and withdrawal rates, the rates and types of surgical interventions and 
complications, and preference-based utility values.  With the exception of the utility data, in the 
existing TAs the evidence required was sourced from clinical trial data.   While the current IBD audit 
collects some information on the majority of these areas for the individual patients and for the 
hospitals taking part, there are some obvious omissions and one of the key issues is the timing of the 
data collection.   
Looking at the evidence that could be used to compare providers, the Organisational audit would 
provide aggregate numbers on surgeries performed per hospital and the Inpatient care audit would 
provide some data on the indication for surgery, the surgical procedure and surgical complication 
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rates.  However, it not clear if there is sufficient information to adjust for case-mix (for example 
severity of condition, described using a standardised clinical measure) which could affect surgical 
success rates.   The mandatory biologic audit would provide some of the information require to 
compare these pharmaceutical interventions (for example withdrawal rates and the reason for 
discontinuation together with the dates of these), but it is not clear if all data needed is collected 
(for example remission or relapse rates and associated dates), and again some validated measure of 
severity of condition, such as the CDAI, would be required to use these data in an economic model.   
As mentioned earlier, the EQ-5D is collected in the patient questionnaire.  However, this instrument 
ĂƐŬƐƉĂƚŝĞŶƚƐ ƚŽĚĞƐĐƌŝďĞƚŚĞŝƌŚĞĂůƚŚƌĞůĂƚĞĚƋƵĂůŝƚǇŽĨ ůŝĨĞ  ‘ƚŽĚĂǇ ? ? Ɛ ƚŚĞƌĞ ŝƐŶŽŽƚŚĞƌWZKDŽƌ
indicator of disease severity in the questionnaire, it will not be possible to link these responses to 
health states defined within an economic model such as remission, relapse or treatment related 
adverse events.  In addition, as the evidence is collected post discharge, the patients will not provide 
responses relating to surgery or surgical complications.  It may be possible to use a published 
statistical relationship to predict utility values from the reported CDAI scores for patients with 
CD.(62) While the CDAI is currently collected in the IBD audit, the timing of collection of the EQ-5D 
and CDAI differ, consequently the evidence will be of limited value for informing the utility values 
required for an economic evaluation.  For these data to be useful for economic modelling purposes, 
they need to be collected at the same time, particularly as IBD is characterised by periods of  ‘ĨůĂƌĞƐ ?
and remission.   
While it is believed that the EQ-5D will be retained in the IBD patient questionnaire, it is not known if 
there are any planned or ongoing studies directly related to the inclusion of additional PROMs in the 
IBD audit.[personal communication Kajal Mortier, project coordinator, May 2014]   The recently 
reported initial results for the CD PROM (PRO2 and PRO3) derived from items within the CDAI are 
promising and this may provide an alternative worthy of consideration (see section 4.3).(25;69)  
However, this would still leave gaps in the evidence base required for surgical procedures and 
pharmaceutical related adverse events.  To our knowledge, there is also no equivalent PROM or 
published relationship between a clinical measure and preference-based utility measure for patients 
with UC, or for paediatric patients at the moment.   
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4.4 Recommendations for IBD 
Table 3 summarises the recommendations and associated future research for IBD. In summary, the 
EQ-5D appears to be appropriate in adults with IBD, and the current IBD audit collects much of the 
information required to conduct economic evaluations.  However there are caveats associated with 
these conclusions which require consideration.  The PedsQL appears to be the most appropriate 
measure for paediatrics, but there are limitations with the usefulness of this measure for economic 
evaluations.  The issues and corresponding potential recommendations (PR) and areas for future 
research (FR) are discussed below.  All suggested future research areas are indicative and would 
require a discussion and detailed proposal if required. 
The conclusion that the EQ-5D is appropriate in adults was informed by just two studies involving 
patients with either CD or UC, and only one of the studies assessed the EQ-5D UK preference-based 
index.  The evidence used in the TAs indicated that there was a dearth of robust EQ-5D evidence in 
this population, particularly in adults at the more severe end of the disease spectrum, in paediatrics, 
and in patients undergoing surgical interventions related to their condition.  EQ-5D data collected in 
the current IBD patient questionnaire could greatly enhance the evidence base in this area if it could 
be linked in some way to clinical severity (see PR.4 below).  This would reduce uncertainty in future 
economic evaluations used to inform policy decisions in the UK and in particular, would enable 
comparisons of biologics as used in routine clinical practice.   
The evidence suggested there may be a ceiling effect in the EQ-5D in adults with less severe disease. 
However, these patients are unlikely to be among those hospitalized for treatment of their IBD 
condition.   The inclusion of the new five level tool (EQ-5D-5L) could potentially reduce the observed 
ceiling effects,(70) once the preference-based weights have been confirmed.  However, the 
psychometric properties of this questionnaire have not been assessed in patients with IBD and this 
would require additional research (PR.1, FR.1).  This would involve the concurrent collection of a 
measure against which the EQ-5D could be assessed, together with additional information such as 
patient demographs, recent  surgical procedures and outcomes, current medications etc. 
The IBD NCA includes patients of all ages (including paediatrics) while the EQ-5D is specifically 
targeted at adults (over age 18 years).  The results of the literature review for paediatrics suggests 
the PedsQL
TM
 is the most appropriate measure for inclusion in the NCA, augmented with the 
PedsQL
TM
 GI module once validated (PR.2).  However, there is no existing method to generate 
utilities from this instrument, so its usefulness for economic evaluations is limited.  Research to 
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generate an associated preference-based measure would require collaboration with the developers 
of the PedsQL
TM
.  This could be directly through preference-weights for the PedsQL
TM
, or indirectly 
using a mapping function from the PedsQL
TM
 to one of the alternative paediatric preference-based 
measures. This is worth considering given that the PedsQL
TM
 has different versions for different age 
groups and also has both patient report and proxy-report versions.  Alternatively, the inclusion of a 
validated preference-based measure specifically designed for paediatrics (such as the CHU-9D or 
HUI2 for younger children and the EQ-5D-Y for adolescents)(1-3) is an option which might be 
considered in the interim to ensure that the NCA data can be used to inform economic evaluations 
(PR.3).  Again, the psychometric properties of the measures included would need to be assessed in 
this population (FR.3). 
As mentioned previously, a review of the latest TA conducted by the National Institute for Health 
and Care excellence (NICE) ?ƐĞĐŝƐŝŽŶ^ƵƉƉŽƌƚhŶŝƚ ?ƐƵŐŐĞƐƚĞĚ that the use of a mechanism to map 
from condition severity to preference-based utility measures could potentially improve the 
methodology (as described in Figure 2) and reduce the uncertainty in the results generated from CD 
cost-effectiveness models.(62)   There is at least one published function which could be used to map 
between the CDAI and the EQ-5D-3L, suitable for adults with CD, but no known functions for UC or 
paediatrics.(66)  This methodology would require concurrent collection of the EQ-5D and the clinical 
measure (e.g. the CDAI and the PCDAI for CD, and equivalent measures for UC) (PR.4).  An 
alternative would be to identify a suitable PROM for inclusion in the patient questionnaire.  As 
discussed earlier, the PRO2 or PRO3, which could potentially be used within a cost-effectiveness 
model, might be suitable for CD, but no known equivalents are available for either UC or paediatrics. 
For this evidence to be used in economic modelling, research would be required to generate 
mapping functions between the clinical and preference-based measures in adults and in paediatrics 
separately for patients with CD and patients with UC (FR.5). 
The IBD audit collects a wealth of information on the clinical status of patients admitted to hospital 
for treatment of their condition, and the associated interventions and care received whilst in 
hospital and on discharge.  However, it is not clear if there is sufficient detailed mandatory 
information on variables such as response to treatments, relapse and clinical activity, to inform all 
parameters required for an economic model.  Additional mandatory fields to capture this 
information would considerably increase the flexibility of secondary use of the data (PR.6).  Formal 
detailed recommendations of which fields to include would require additional detailed inspection of 
the exact data collected in the current IBD audit (FR.6).   
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Finally it is recommended that the proposed links between the IBD audit and the new IBD register 
(see Section 4.3.3) are utilised to make full use of the clinical and PROM data that will be available 
(PR.7). 
Table 3: Recommendations and associated future research for IBD 
PR.1 Include the new version of the EQ-5D (EQ-5D-5L) in future adult patient questionnaires 
FR.1 Assess the psychometric properties of the EQ-5D-5L in adults with IBD using data collected 
in the audit 
PR.2 Include the PedsQL
TM 
(and the PedsQL
TM
 GI module) in future paediatric patient 
questionnaires 
FR.2 Investigate potential collaboration with the developers of the PedsQL
TM
 with a view to 
developing a methodology to generate preference-based utility measures directly or 
indirectly (via mapping to alternative measure) from the PedsQL
TM
 
PR.3 Include age related paediatric preference-based HRQoL instrument (e.g. CHU-9D, HUI2 and 
EQ-5D-Y) in future paediatric patient questionnaires 
FR.3 Assess the psychometric properties of the paediatric preference-based tools in IBD using 
data collected in the audit 
PR.4 Synchronise the timing of collection of a clinical measure (such as the CDAI  for patients 
with CD, or the CAI for patients with UC) and the HRQoL measure 
FR.4 Conduct analyses to generate mapping functions between the suggested clinical and 
preference-based measures to enable the evidence to be used in economic models 
PR.5 Include an additional PROM to capture disease severity, such as the PRO2 or PRO3 (and 
equivalent measures for UC and paediatrics), in the patient questionnaire 
FR.5 Assess the validity of the PRO2/PRO3 using data collected in the audit 
FR.6 Conduct research to generate equivalent condition severity PROMs in adults and 
paediatrics with UC 
PR.6 Include additional mandatory fields in the IBD audit such as response to current treatment, 
relapse and current disease activity (linked by time to HRQoL) 
FR.7 Detailed analyses of fields currently collected in the IBD audit to identify recommendations 
for future mandatory fields 
PR.7 Utilise links between the IBD audit and the new IBD register 
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5. SUMMARY
5.1 Summary of evidence used to inform the conclusions for WP1.1 and WP1.2 
In summary, a review of primary studies (n=2) provides evidence of acceptability, reliability, and 
known group/convergent validity for the EQ-5D in adults with IBD (Table 4).  However the evidence 
on the responsiveness of the EQ-5D is mixed with some ceiling effects and potential insensitivity to 
changes over time reported.  While the EQ-5D is considered to be acceptable, additional validation is 
required particularly in patients with severe IBD and those undergoing surgical procedures.  A review 
of evidence of PROMs for paediatrics provides evidence of acceptability, reliability and known 
group/convergent validity for the PedsQL
TM
 (5 studies) in paediatrics with IBD (Table 4).  The 
PedsQL
TM
 does not currently have an associated preference-base tariff, but it has both self-report 
and parent/carer versions and covers the full age spectrum for paediatrics (2-18 years).  Additional 
preference-based measures are also recommended for use in paediatrics with IBD. 
Table 4: Summary of evidence currently available for recommended measure(s) 
Measure N Acceptability Reliability Construct Responsiveness Overall 
KGV Convergent Change 
over 
time 
Ceiling 
Effect 
EQ-5D 2 Good Good Good Good Mixed Mixed Acceptable 
but not 
appropriate 
for 
paediatrics 
PedsQL 5 Good Good Good NE NE NE Acceptable 
PedsQL GI 
module 
This measure is currently being validated and will be available shortly 
N= number of studies used to inform conclusions, KGV: known group validity; NE: no evidence 
a 
consider the PedsQL GI module as an adjunct to the core measure 
5.2 Summary of evidence required for use in economic evaluations (WP1.3) 
The EQ-5D is currently collected in the IBD audit, but as it is not collected at the same time as other 
key variables used in the economics (for example, surgery or flares in symptoms), its usefulness in 
comparing interventions is limited.  It may be possible to use a clinical variable (for example the CDAI 
in patients with CD) and an existing relationship between the CDAI and EQ-5D to enable the NCA 
data to be used in economic evaluations.  Despite the issue with the timing of collections, the EQ-5D 
would be useful when comparing providers and if the timings of data collection could be 
synchronised with the clinical data, then it could be used in standard economic evaluations.  While 
the audit collects much of the information required to conduct economic evaluations, for example 
the aggregate numbers of surgeries and surgical complications could be used to compare providers, 
it is not clear if there is sufficient evidence to adjust for case-mix.  There are also areas where 
35 
additional evidence, if mandatory, would be beneficial for future economic evaluations.  These 
include details of pharmaceutical interventions and associated response and relapse data collected 
at the same time as a clinical variable such as the CDAI, surgical rates including type of intervention, 
success rate and associated complications. 
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APPENDIX: INFLAMMATORY BOWEL DISEASE  
The tables in this Appendix provide additional information for the reviews (WP1.1, 1.2 and 1.3) conducted for 
IBD. 
Table A1: Characteristics of studies included in the systematic review of primary studies for IBD 
Study 
ref 
Author, 
Year 
Country  Disease/treatment 
stage 
Treatment (if 
any) 
Study type (e.g. 
cross sectional, 
RCT, cohort) 
Study objective 
Konig, 
2002(6) 
Germany Patients with 
inflammatory bowel 
ĚŝƐĞĂƐĞ ?ĞŝƚŚĞƌƌŽŚŶ ?Ɛ
disease or ulcerative 
colitis) 
No treatment, 
single cohort 
Questionnaires 
given 2 times, 
two weeks apart 
Consecutive 
patients 
attending 
outpatient 
appointments 
To analyse the 
construct validity, 
criterion validity, test-
retest reliability and 
responsiveness of the 
EQ-5D 
Stark, 
2010(7) 
Germany Patients with 
inflammatory bowel 
ĚŝƐĞĂƐĞ ?ĞŝƚŚĞƌƌŽŚŶ ?Ɛ
disease or ulcerative 
colitis), 18 years or 
older  
Treatment not 
reported 
Random sample 
of members of 
German IBD 
association 
To assess validity, 
reliability, and 
responsiveness of EQ-
5D, especially the 
responsiveness to 
meaningful differences 
in patient reported 
changes in health 
status  
RCT, randomised controlled trial; IBD, Inflammatory bowel disease;  ?ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ ?h ?ƵůĐĞƌĂƚŝǀĞĐŽůŝƚŝƐ 
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Table A2: Participant characteristics studies in the systematic review of primary studies for IBD 
Study 
ref 
Author, 
Year 
Number of 
participants 
recruited 
Age in 
years 
mean 
(sd); 
range 
male 
% 
Ethnicity Other 
characteristics 
Missing data (patients completing 
study) include reasons for non-
completion if given 
Konig, 
2002(6) 
152 41.4 
(12.6); 
17-73 
52% NR ƌŽŚŶ ?Ɛ
disease: 80.9% 
Ulcerative 
colitis: 19.1% 
Age at 
diagnosis: 27.1 
(sd 11.3) yr 
Duration of 
disease: 13.9 
(sd 8.5) yr 
Remission: 
62% 
Active disease: 
38% 
Some data are missing for 6  patients 
with ileostomy 
Stark, 
2010(7) 
502 42 
(11); 
17-83 
41% NR ƌŽŚŶ ?Ɛ
disease: 
53.78% 
Ulcerative 
colitis: 46.21% 
Age at 
diagnosis: 29 
(sd 11) yr 
Duration of 
disease: 14 (sd 
8) yr
Remission: 
59.6% 
Active disease: 
40.4% 
447 patients returned follow-up 
questionnaires 
Some (n<5) data missing from some 
analyses  
Reasons NR 
^ ?ƐƚĂŶĚĂƌĚĚĞǀŝĂƚŝŽŶ ?Ǉƌ ?ǇĞĂƌ ?EZ ?ŶŽƚƌĞƉŽƌƚĞĚ ? ?ƌŽŚŶ ƐĚŝƐĞĂƐĞ ?h ?ƵůĐĞƌĂƚŝǀĞĐŽůŝƚŝƐ 
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Table A3: Valuation and descriptive methods used in the systematic review of primary studies for IBD 
  GENERIC MEASURES OTHER MEASURES USED 
Study 
ref 
Author, 
Year 
Descriptive 
system  
Tariff used  Mean  
(SD); 
95% CI 
Condition-
specific 
HRQL 
measures  
Clinical 
measures  
Qualitative 
questions  
Missing data; 
completion 
rates of 
measures; etc.  
Konig, 
2002(6) 
EQ-5D German,(8) 
(range 0-
100) 
 None IBDQ 
CDAI 
CAI 
none Acceptance of 
EQ-5D 
assessed by 
proportion of 
missing 
responses on 
EQ-5D 
SF-36 
health 
dimensions 
 
Stark, 
2010(7) 
EQ-5D UK (10) and  
German (9) 
At 
baseline 
 
UK tariff 
CD: 0.77 
(SD 0.24; 
median 
0.8) 
UC: 0. 84 
(SD 0. 18; 
median 
0. 85) 
None CDAI 
CAI 
None NR 
/Y ?/ŶĨůĂŵŵĂƚŽƌǇŽǁĞůŝƐĞĂƐĞYƵĞƐƚŝŽŶŶĂŝƌĞ ?/ ?ƌŽŚŶ ?ƐŝƐĞĂƐĞĐƚŝǀŝƚǇ/ŶĚĞǆ ?/ ?ůŝŶŝĐĂůActivity 
/ŶĚĞǆ ?^ ?ƐƚĂŶĚĂƌĚĚĞǀŝĂƚŝŽŶ ? ?ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ ?h ?ƵůĐĞƌĂƚŝǀĞĐŽůŝƚŝƐ 
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Table A4: Acceptability, reliability and validity assessment in IBD 
Author, 
Year 
Method of measuring validity 
Type of validity, how (e.g. 
known group/convergent)? 
Validity results 
Group A(n) vs. Group B(n)
Ƈ
 
Mean EQ-5D; mean difference 
in EQ-5D 
ƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ ?ŶŽƚĞƐ 
Konig, 
2002(6) 
 
Acceptability, assessed by 
proportion of missing 
responses 
EQ-5D missing range: 0.7 to 
3.3% 
IBDQ missing range: 2.0% to 
9.2% 
As shown by the low 
proportions of missing 
responses, the EQ-5D was well 
accepted in this population 
 
The EQ-5D index showed 
ceiling effects hence it may not 
be able to discriminate health 
states in patients with less 
severe disease 
 
The construct/concurrent 
validity results were good on 
the whole 
 
The test-retest results were 
good 
Reliability (test-retest), kappa 
statistic 
 
80.5% of outpatients 
completed the 2
nd
 EQ-5D 
52 (79%) reported no change, 
12 (18%) reported an 
improvement 
 
EQ-5D health dimension (n): 
agreement (%), Kappa statistic 
Mobility (52): 47 (90.4%), 0.39 
Self-care (52): 52 (100.0%), 1.00 
Usual activities (52): 46 
(88.5%), 0.73 
Pain/discomfort (50): 43 
(86.0%), 0.74 
Anxiety/depression (51): 41 
(80.4%), 0.61 
Construct validity (convergent), 
Spearman rank correlation 
 
EQ-5D and CDAI correlation = -
0.48
* 
EQ-5D and CAI correlation = -
0.66
** 
 
Construct validity (convergent), 
Spearman rank correlation 
 
Correlations between EQ-5D 
and IBDQ ranged from 0.52 to 
0.62 (p<0.0001 for all) 
Construct validity (known 
group), remission vs active 
disease, various statistical tests 
used 
 
Remission (% no; moderate; 
extreme problems) 
Mobility: 96.1; 3.9; 0 
Self-care: 98.7; 1.3; 0 
Usual activities: 90.7; 9.3; 0 
Pain/discomfort: 58.1; 41.9; 0 
Anxiety/depression: 70.3; 27.0; 
2.7 
 
Active (% no; moderate; 
extreme problems) 
Mobility: 66; 29.8; 4.3, 
p<0.0001
a
 
Self-care: 83.0; 12.8; 4.3, 
p=0.0019
 b
 
Usual activities: 42.6; 42.6; 
14.9, P<0.0001
 a
 
Pain/discomfort: 23.9; 67.9; 
8.7, NR 
Anxiety/depression: 44.7; 51.1; 
4.3, p=0.005
 a
 
Construct validity (known 
group), Inpatients vs. 
Outpatients (% no; moderate; 
extreme problems) 
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outpatients, various statistical 
tests used 
 
Mobility: 90.0; 10; 0 
Self-care: 96.7; 3.3; 0 
Usual activities: 74.0; 24.4; 1.7 
Pain/discomfort: 44.0; 54.3; 
1.7 
Anxiety/depression: 59.3; 36.4; 
4.2 
 
Inpatients (% no; moderate; 
extreme problems) 
Mobility: 64.5; 29.0; 6.5, 
p=0.0013
b
 
Self-care: 77.4; 16.1; 6.5, 
0.0015
b
 
Usual activities: 41.9; 38.7; 
19.4, 0.0007
a
 
Pain/discomfort: 38.7; 48.4; 
12.9, 0.5994
a
 
Anxiety/depression: 51.6; 41.9; 
6.5, 0.4394
a
 
 
Significantly better response 
levels for outpatients 
(compared to inpatients) 
observed for: mobility, self-
care, usual activities. For 
pain/discomfort and 
anxiety/depression difference 
was small and not significant. 
Stark, 
2010(7) 
Reliability (test-retest), patients 
who reported no change in 
health. Simple kappa to test 
categorical variables; ICC using 
2-way ANOVA to test 
continuous variables 
Kappa statistic 
Substantial to almost perfect 
agreement for all EQ-5D health 
dimensions 
UK index ICC 
All: 0.76 
CD: 0.76 
UC: 0.73 
Same health: the mean EQ-5D 
score in those reporting the 
same health was higher in all 
groups and significantly higher 
in the overall group, those with 
CD, and those with active 
disease 
The reliability of the EQ-5D 
index scores in test Wretest was 
good, but the ICCs and thus the 
reliability of the EQ-5D index 
scores were lower than that of 
the VAS score. 
 
Construct validity (convergent), 
Spearman rank correlations  
UK index 
EQ-5D and CDAI in CD patients: 
r= -0.75 (p<0.0001) 
EQ-5D and CAI in UC patients: 
r= -0.65 (p<0.0001) 
The construct validity of the 
EQ-5D in IBD subjects, i.e., its 
agreement with accepted 
disease criteria, was good, and 
it was able to discriminate 
between those with active 
disease and those in remission.  
 
UK index scores of subjects in 
remission were significantly 
better than those with active 
disease  
Construct validity (known 
group), active disease vs 
remission. Statistical test type 
not reported.  
EQ-5D UK index  
Mean (SD)  
CD remission: 0.89 (0.13), range 
(0.26-1.00) 
CD active: 0.61 (0.29), range (-
0.18 W1.00), p <0.0001  
UC remission: 0.91 (0.14), range 
(0.23 W1.00)  
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UC active: 0.71 (0.18), range 
(0.09 W1.00), p <0.0001 
All EQ-5D health dimensions 
showed significant differences 
between remission and active 
disease except self-care in UC 
Ŷ ?ŶƵŵďĞƌ ?/Y ?/ŶĨůĂŵŵĂƚŽƌǇŽǁĞůŝƐĞĂƐĞYƵĞƐƚŝŽŶŶĂŝƌĞ ?/ ?ƌŽŚŶ ?ƐŝƐĞĂƐĞĐƚŝǀŝƚǇ/ŶĚĞǆ ?/ ?
ůŝŶŝĐĂůĐƚŝǀŝƚǇ/ŶĚĞǆ ? ?ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ ?h ?ƵůĐĞƌĂƚŝǀ ĐŽůŝƚŝƐ ?/ ?ŝŶƚƌĂĐůĂƐƐĐŽƌƌĞůĂƚŝŽŶĐŽĞĨĨŝĐŝĞŶƚ ?
ANOVA, analysis of variance; 
x
p<0.0001, Spearman rank; 
**
p<0.001, Spearman rank; 
a
Chi squared test with 
ĐĂƚĞŐŽƌŝĞƐ ‘ŵŽĚĞƌĂƚĞƉƌŽďůĞŵƐ ?ĂŶĚ ‘ĞǆƚƌĞŵĞƉƌŽďůĞŵƐ ?ĐŽůůĂƉƐĞĚŝŶƚŽŽŶĞĐĂƚĞŐŽƌǇĚƵĞƚŽƐŵĂůůĞǆƉĞĐƚĞĚ
ŶƵŵďĞƌŽĨŽďƐĞƌǀĂƚŝŽŶƐ ?AM ? ?ŝŶ ‘ĞǆƚƌĞŵĞƉƌŽďůĞŵƐ ?ĐĂƚĞŐŽƌǇ ? 
b&ŝƐŚĞƌ ?ƐĞǆĂĐƚƚĞƐƚǁŝƚŚĐĂƚĞŐŽƌŝĞƐ ‘ŵŽĚĞƌĂƚĞƉƌŽďůĞŵƐ ?ĂŶĚ ‘ĞǆƚƌĞŵĞƉƌŽďůĞŵƐ ?ĐŽůůĂƉƐĞĚŝŶƚŽŽŶĞĐĂƚĞŐŽƌǇ
ĚƵĞƚŽƐŵĂůůĞǆƉĞĐƚĞĚŶƵŵďĞƌŽĨŽďƐĞƌǀĂƚŝŽŶƐ ?AM ? ?ŝŶ ‘ŵŽĚĞƌĂƚĞƉƌŽďůĞŵƐ ?ĂŶĚ ‘ĞǆƚƌĞŵĞƉƌŽďůĞŵƐ ?
categories. 
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Table A5: Responsiveness assessment in IBD  
Author, 
Year 
ref 
Method of 
measuring 
responsiveness 
(e.g. effect 
sizes, 
statistical 
significance) 
Responsiveness results 
 
ƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ ?ŶŽƚĞƐ 
Konig, 
2002(6) 
 
Responsiveness 
(ceiling effect), 
% scoring full 
health 
Ceiling effect observed on EQ-5D 
(59.7% rated at least 4/5 items on EQ-5D as 
 ‘ŶŽƉƌŽďůĞŵƐ ? W 25% scored EQ-5D =1 
 
Stark, 
2010(7) 
Responsiveness 
(ceiling effect), 
% reporting full 
health 
31% of CD and 43% of UC patients reported 
full health 
Indicative of a ceiling effect 
Stark, 
2010(7) 
Patients who 
reported a 
change in 
health in the 
transition 
question. T-
test of 
difference in 
means. 
Mean Difference (Mean (SD (n)) for worse; 
same; improved 
UK Index) 
All: -0.09 (0.168* (26)); 0.019 (0.14* (357)); 
0.095 (0.142*** (41)) 
CD: -0.102 (0.206 (16)); 0.026 (0.155* (194)); 
0.070 (0.134* (21)) 
UC: -0.07 (0.083*(10)); 0.011 (0.123 (163)); 
0.123 (0.148**(20)) 
Active: -0.098 (0.209 (15)); 0.047 (0.20** 
(121)); 0.148 (0.135***(20)) 
Remission: -0.084 (0.102* (9)); 0.007 (0.092 
(195)); 0.038 (0.134 (19)) 
Improved health : 
Changes in EQ-5D index scores were 
statistically significant (p<0.001) for patients 
reporting improved health except in those in 
remission. 
Worse health: 
The mean EQ-5D score in those reporting 
worse health was lower in comparison to 
subjects reporting stable health in all 
subgroups, but it was only significantly 
different in the overall group, UC subjects, 
and subjects in remission 
EQ-5D failed to respond in some 
subgroup analyses, though 
overall changes were seen.  This 
may reflect the low power in 
these groups (n: 9 W21) or it may 
be that the change in health 
status is not captured by the 
questions of the EQ-5D.. 
 
The EQ-5D index score was most 
responsive (large ES and SRM) 
for subjects with active disease 
who reported improved health 
and for subjects in remission 
who reported worse health 
 
 
Stark, 
2010(7) 
Patients who 
reported a 
change in 
health in the 
transition 
question. 
Standardised 
response mean 
(SRM).
a
 
Standardised Response Mean (worse; same; 
improved) 
UK index 
All: -0.53; 0.13; 0.67 
CD: -0.49; 0.17; 0.52 
UC: -0.84; 0.09 0.83 
Active: -0.47; 0.24; 1.10 
Remission: -0.82; 0.07; 0.28 
 
Improved health: direction of effect as 
expected in all groups, but only a strong effect 
(SRM>0.8) in UC and active disease 
Worse health: direction of effect as expected 
in all groups, but a strong effect (SRM>0.8) 
only seen in UC and those in remission 
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Patients who 
reported a 
change in 
health in the 
transition 
question. 
Effect size 
(ES).
b
 
UK index (worse; same; improved health) 
All: -0.33; 0.09; 0.55 
CD: -0.32; 0.11; 0.43 
UC: -0.68; 0.06; 0.66 
Active: -0.38; 0.18; 1.06 
Remission: -0.63; 0.05;0.22 
All had effect sizes in the expected direction, 
but only data in patients with active disease 
who reported improved health showed a 
strong effect size (>0.8) 
^ ?ƐƚĂŶĚĂƌĚĚĞǀŝĂƚŝŽŶ ?Ŷ ?ŶƵŵďĞƌ ? ?ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ ?h ?ƵůĐĞƌĂƚŝǀĞĐŽůŝƚŝƐ ?^ZD ?^ƚĂŶĚĂƌĚŝƐĞĚƌĞƐƉŽŶƐĞ
mean; ES, effect size. 
a
 calculated by dividing the difference of the means at the 2 timepoints by the SD of the differences of scores 
between the 2 timepoints 
b
 calculated by dividing the difference of the means at the 2 timepoints by the standard deviation (SD) of the 
baseline mean which relates the change to the baseline SD 
*P < 0.05; **P < 0.01; ***P < 0.0001.
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Table A6: Measures reviewed or used in the seven studies included in the paediatric systematic review in IBD 
 Abdovic 
2013(44) 
Duffy 
2011(45) 
Marcus 
2009(46) 
Perrin 
2008(47) 
Upton 2005(48) Ogden 
2011(40) 
Lane 2012 
(50) 
Varni 
2014(49) 
Study objective and population Children 
 ?A? ?
years) 
 CD=74 
UC=30 
 
Description 
of HRQoL 
measures 
used in 
children 
with IBD 
Examined 
fatigue in 
children (X-x 
years) 
with IBD 
(n=70) 
compared to 
controls 
(n=157) 
 
Evaluated the 
Impact 
Questionnaire 
in children (8-
18 years) with 
UC=59 
CD=161 
Assessed the UK 
version of the 
PedsQL v4 in a 
mixed sample 
including IBD 
Total (IBD) 
children=1399(76) 
Total (IBD) 
parents =970 (67) 
 
Age 8-18 years 
Validate 
the 
IMPACT-III 
(UK) in 
British 
children (8-
17 years) 
with IBD 
CD=64 
UC=12 
IC=21 
Conference 
abstract of 
Varni 2014 
Assess 
psychometric 
properties of 
PedsQL GI 
module in  
paediatrics 
(3-18 years) 
with a broad 
range of GI 
disorders  
CD=192 
UC=67 
         
IMPACT-III (51;52;56) Yes Yes Yes
 
- 
- 
Yes - - 
IMPACT-II questionnaire(51;52) - Yes   Yes  
- 
 - - 
PCDAI (severity)(54)  - - Yes  Yes  
- 
 - - 
CDI (57) - Yes  Yes  - 
- 
 - - 
         
CHQ(58)  - 
- 
- - 
- 
yes - - 
PedsQL fatigue(46;51;71) 
 
- Yes 
 
 
Yes - -  - - 
PedsQL 4.0  
[varni 1999, (4;72-75) 
Yes  Yes Yes  Yes  Yes   Yes Yes
 
PedsQL GSM (49) - - - - -  Yes  
De-novo GI 
module 
Yes 
 
De-novo GI 
module
 
#
Croatian adaptation of the IMPACT-/// ?WWĂĞĚŝĂƚƌŝĐƌŽŚŶ ?ƐĚŝƐĞĂƐĞĂĐƚŝǀŝƚǇŝŶĚĞǆ ?/ŝŶĚĞƚĞƌŵŝŶĂƚĞĐŽůŝƚŝƐ, CDI ŚŝůĚƌĞŶ ?ƐĞƉƌĞƐƐŝŽŶ/ŶǀĞŶƚŽƌǇ 
CHQ Child Health Questionnaire, PedsQL Paediatric Quality of Life Inventory 
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Table A7: IBD specific and generic measures used in the studies included in the paediatric systematic review in IBD 
IBD specific measures Generic measures 
IMPACT-III PCDAI Child health 
questionnaire 
(CHQ)[waters 
2009] 
PedsQL 
4.0 
generic 
core 
scales 
[Varni 
2001] 
PedsQL 
Multi-
dimensional 
Fatigue 
Scale 
[Griffiths 
2009] 
PedsQL 
GI module 
[Varni 2014] 
ŚŝůĚƌĞŶ ?Ɛ
depression 
inventory (CDI) 
[kovacs 2003 
Age(years) A? ?ǇĞĂƌƐ paediatrics 4-19 2-18 2-18 2-18 A? ?ǇĞĂƌƐ 
Respondent Child Clinician Child/parent Child/par
ent 
Child/parent Child/parent Child 
Items 35 87 23 18 74 35 
Domains 6 3 10 4 3 24 6 
Total summary score 35-175 0-100 2x summary 
scores 
0-100 
2x 
summary 
scores 
0-100 
3x summary 
scores 
0-100 
Scores range 
0-100 
35-175 
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Table A8: Mandatory fields collected in the IBD NCA (Inpatient care) 
INPATIENT UC CARE AUDIT TOOL (all questions mandatory) 
Separate adult and paediatric tools, Questions below taken from adult version 
PRE-SECTION PATIENT DEMOGRAPHICS
 
 WĂƚŝĞŶƚĂƵĚŝƚŶƵŵďĞƌ ?ĂƵƚŽŵĂƚŝĐĂůůǇĂůůŽĐĂƚĞĚ ? ?WĂƚŝĞŶƚ ?ƐĂŐĞ ƚĂĚŵŝƐƐŝŽŶ ?^Ğǆ 
SECTION ONE: ADMISSION/MORTALITY 
 
 Admission: Date of admission to this hospital, What was the primary reason for admission (elective 
admission for established active UC, emergency admission for established active UC, transferred from 
another site for surgery or further medical treatment, Elective admission for surgery, new diagnosis of 
UC, other) 
Discharge/Mortality: Was the patient (dates): discharged home, transferred for surgery or further 
medical management , deceased, Was death UC related  
SECTION 2: ASSESSING THE EXTENT OF ULCERATIVE COLITIS
 
 IBD team/ward: When was the patient first seen by a member of the IBD team? Was the patient: seen by 
an IBD Nurse specialist during admission, transferred to a specialist gastroenterology bed 
Patient history: What was the extent of the colitis? (proctitis, left sided, extensive, unknown), Has the 
patient had previous admissions with UC in the two years prior to this admission? If yes (how many times, 
Has there been a related admission within the last 30 days? Patient already been included in this audit?  
Comorbidity: Did the patient have any significant comorbid diseases (none, diabetes, cardiovascular 
disease, liver disease, respiratory, active cancer, renal failure, other) 
Severity of Disease: How many loose or bloody stools were passed in the first full day following 
admission, Date a stool sample sent for Standard Stool Culture, Stool culture positive (Y/N) 
SECTION 3: MEDICAL INTERVENTIONS 
 Venous thromboembolism: Was the patient given prophylactic heparin, Did the patient have a thrombotic 
episode during this admission 
 Weight assessment and Dietetic support during admission: Nutritional risk assessment undertaken, 
ŝĞƚŝƚŝĂŶƐĞĞƚŚĞƉĂƚŝĞŶƚĚƵƌŝŶŐĂĚŵŝƐƐŝŽŶ ?WĂƚŝĞŶƚ ?ƐǁĞŝŐŚƚŵĞĂƐƵƌĞĚ ?ŝĞƚĂƌǇƚƌĞĂƚŵĞŶƚŝŶŝƚŝĂƚĞĚ 
Steroid therapy: Were corticosteroids prescribed during admission, If yes, which (IV /oral corticosteroids) 
Which other therapies were started during the admission: Ciclosporin , Anti-TNF, Clinical trial or significant 
other medical therapies, Name of trial or therapy, Decision to treat discussed at MDT meeting  
SECTION 4: SURGICAL INTERVENTIONS  
  Surgical therapy: Did patient have surgery (date), Indications for surgery (e.g. failure of medical therapy, 
high grade dysplasia, abscess, closure of stoma, obstruction etc), Seen by a stoma nurse   
Surgical complications: e.g. no complications, deep vein thrombosis, wound infection, small bowel 
obstruction, respiratory, stoma complications, other etc 
SECTION 5: DISCHARGE ARRANGEMENTS  
  If the patient was discharged on steroids was bone protection prescribed, Was patient on 
immunosupressives on discharge or was there a clear plan to start, Plan for maintenance Anti-TNF on 
discharge, Was the plan for follow up documented in the notes,  If yes, how was the follow- up specified  
SECTION 6: OUTPATIENT CARE PRIOR TO ADMISSION
 
 What was the date of the last clinic review, Was disease active at last OPD appointment, If yes, was 
patient admitted to hospital at this time, If not admitted, was treatment changed, If yes: for 5 ASA, 
Steroids, Topical, Immunosuppressant: Started/Increased, Stopped/Decreased, Not changed 
Prolonged steroid use: Has the patient been prescribed steroids for > 3 months during past 12 months, If 
yes, what steroid sparing strategies were tried , What was the outcome of the steroid sparing strategy 
Anaemia PtŚĂƚǁĂƐƚŚĞƉĂƚŝĞŶƚ ?Ɛ,ďŽŶĂĚŵŝƐƐŝŽŶ ?/ĨƉĂƚŝĞŶƚǁĂƐĂŶĂĞŵŝĐŚŽǁůŽŶŐƉƌŝŽƌƚŽĂĚŵŝƐƐŝŽŶ
was this known, If iron deficient, what treatment was provided, Did the patient tolerate this treatment  
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Table A9: Mandatory fields collected in the IBD NCA (Organisational) 
ORGANISATIONAL AUDIT TOOL (separate adult and paediatric tools; text (from adult text) indicative of areas 
covered; all questions mandatory; all refer to one year audit period unless stated otherwise)  
SECTION ONE: DEMOGRAPHICS 
Number of IBD patients (split by CD, UC, IBDU, adult/paediatric): Total service, New, Readmitted < 30 
days of discharge, newly-started on Infliximab (adalimumab), admitted primarily for treatment of IBD 
died during that admission 
Number of  ileo-anal pouch surgery performed on site  
Staff: How many WTE staff in IBD team (e.g. gastroenterologists, colorectal surgeons, IBD nurse 
specialists, stoma nurses, detitians, administrators) 
SECTION 2: PATIENT EXPERIENCE
IBD information provided: how to access IBD services, follow up, educational material, 'patient education' 
session, regular education opportunities for all IBD patients and their families, clear guidance on how 
patients can seek a second opinion, Rapid access to specialist advice such as telephone, email, or face to 
face review for relapse patients , exercise choice between treatments, written information about IBD and 
a range of treatments, access to a translator for all face to face and telephone contacts, information is 
available that is appropriate to the age, understanding and communication needs of the patient, A 
selection of written information is available for patients in languages other than English 
Patient involvement: actively involved in management decisions about care, clear structured pathway for 
patient to discuss treatment with MDT, IBD patient panel, Involvement of patients in service planning and 
improvement , patients given opportunity to provide feedback on their care, Reporting, followed by 
action planning and change implemented as a result of the patient feedback of care  
Education of patients and support groups: Newly-diagnosed patients offered education with an IBD 
nurse/dietitian, Regular education opportunities, open forum meeting which meets at least annually, 
Information and support for patient organisations, local patient support groups 
SECTION 3: CLINICAL QUALITY 
The IBD team: Levels of staff and access to specialists: Clinical lead, consultant gastroenterologist, IBD and 
stoma nurse, dietitian, consultant colorectal surgeon; Clear pathway for referral to rheumatologist, 
support from: radiologist, pharmacist, defined access to ophthalmologist; per 250,000 population has 
(WYE): 0.5 administrative, 2 consultant gastroenterologists, 2 consultant colorectal surgeons, 1.5 IBD and 
1.5 stoma nurse specialists 0.5 WTE gastroenterology dietitians 
Inpatient monitoring: On admission (>50%, >60%, >75%, >90%) patients have weight and nutritional risk 
assessment,  stool sample sent for standard stool culture, regular stool chart documented 
Mental health services: IBD inpatients can receive specialist mental health assessment within the acute 
service (< 48 hour), information available how to access counselling support, can be referred for specialist 
Clinical Psychological support. Secure funding and a clear referral pathway is in place for referral to 
clinical psychology or a counsellor  
Sexual and reproductive health: Written information: IBD in pregnancy, effects on fertility, sexuality and 
body image; pregnancy clinic (or named obstetrician) for all pregnant IBD patients on current medical 
ƚƌĞĂƚŵĞŶƚ ?ĂŐƌĞĞĚĐůŝŶŝĐĂůĐĂƌĞƉĂƚŚǁĂǇĨŽƌƐŚĂƌĞĚĐĂƌĞďĞƚǁĞĞŶƚŚĞǁŽŵĞŶ ?ƐŚĞĂůƚŚĂŶĚ/ƐĞƌǀŝĐĞƐ 
Multidisciplinary working:  MDT meeting where complex IBD cases can be discussed, joint or parallel 
clinics for patients requiring joint medical and surgical care, Decisions from MDT are documented in 
patient notes and fed back. Meetings attended by: gastroenterology dietitian, pharmacist, administrator 
Access to nutritional support and therapy: (>30%, >60%, >75%, all) of IBD patients are reviewed by a 
dietitian during inpatient stay if required, IBD patients can be referred to a dietitian experienced in the 
dietary management of IBD, Enteral nutrition as a primary treatment is avaŝůĂďůĞƚŽƉĂƚŝĞŶƚƐǁŝƚŚƌŽŚŶ ?Ɛ
disease, Information given to all new IBD patients includes nutritional advice, Nutrition MDT available to 
IBD inpatients, All new patients have malnutrition screening, The nutrition NDT includes: specialist 
dietitian and nutrition support nurse, consultant gastroenterologist or consultant colorectal surgeon 
Arrangements for use of immunosuppressives, Prior to starting biological therapies screening for 
tuberculosis, Assessed for risk of infections, Counselled about the risk of malignancy and sepsis, written 
local protocols for administration of biologicals, White blood count measured >= 3 monthly, Clinicians 
have access to a pharmacist with specialist knowledge / interest, Local protocols for administration of 
biological include pre-treatment, actions for infusion reactions and accelerated infusions, There is a clear 
guidance written on action if white cell counts are low, etc. 
Surgery for IBD: Informed consent (risks/benefits), Patients put on Association of Coloproctology of Great 
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Britain and Ireland (ACPGBI) Ileal Pouch Registry, Formal regular governance to review surgical morbidity 
and mortality including review audit of postoperative complications, Facilities/trained surgeons for 
laparoscopic / laparoscopically-assisted surgery, Complex surgical procedures undertaken, Patients 
considered for pouch surgery referred for expert pathological, Nominated lead for IBD surgery, Pouch 
failure (and salvage) managed in, or referred to agreed regional specialist unit, Annual review of IBD 
surgical service with review of activity, mortality and morbidity with regularly reviewed action plan 
Inpatient facilities: Identifiable gastroenterology ward, intensive therapy unit, mixed medical/surgical 
high dependency unit, gastroenterology and colorectal surgical facilities are on the same site, IBD / 
suspected IBD patients usually triaged to the gastroenterology ward on admission. At least one toilet per 
6 (4,3 IBD) patients 
Access to diagnostic services available for: gastrointestinal pathologist assessment before surgery, and 
referral of complex cases to a nationally recognised expert, Ultrasound/CT/contrast studies for inpatients,  
within 24 hours, Routine plain abdominal x-ray on admission, Urgent access to endoscopy (<72 hours), 
histological reports available (<5 days), Urgent histology biopsies (<2 days), Abscess drainage can be 
performed by interventional radiology, Outpatient access to ultrasound/CT/contrast studies and 
endoscopic (<4 weeks), Small bowel MRI available, Consultant radiologist who primarily reports all 
gastrointestinal radiology, Recent audit of reporting and waiting times for CT/MR and endoscopy 
Inpatient care: >(30%, 50%, 75%) patients seen by IBD specialist (<24 hour admission), >(50%, 65%, 75%, 
90%) compliance with risk assessment and prescribing of thromboprophylaxis, >(50%, 65%, 75%, 90%) 
patients receiving discharge steroids placed on steroid reduction programme/covered with bone 
protection agents, Named pharmacist available for inpatient drug reviews, >90% medication history 
reconciled by a pharmacist shortly after their admission, Access to IBD nurse during admission 
There are Trust/Health Board guidelines for the management of acute severe colitis: >75% IBD patients 
placed in gastroenterology /named surgical ward (<24 hours admission) 
There is an acute pain management team available on site, Pain scores are routinely included in nursing 
observations, usual practice to refer inpatient with severe pain to the acute pain management team 
All patients due to have, or have a stoma can be seen by a stoma nurse during admission if required 
SECTION 4: ORGANISATION AND CHOICE OF CARE 
  Referral of suspected IBD patients: Newly-referred patients can go to gastroenterology/surgical clinics, 
agreed referral pathway (between GP's / secondary care) for urgent OPD referrals, All urgent referrals 
seen < 4 weeks (more rapidly if necessary), Guidance developed for GP's for referral/identification of 
symptomatic patients in whom IBD is suspected  
Supporting patients to exercise choice between care strategies for outpatient management: All patients 
under secondary care are reviewed annually, Stable patients referred back to primary care are given a 
clear plan about what to do in the event of flare up, GP routinely given clear instructions on need/criteria 
for annual review (colorectal cancer surveillance, renal function, bone densitometry), Patients offered 
choice of annual review (hospital clinic, telephone clinic, review in primary care) 
Outpatient care: The following are documented for all patients at clinic review: number of liquid stools 
per day, abdominal pain, weight loss. Systems in place to ensure all patients currently under hospital 
review are identified and are offered surveillance colonoscopy, Steroid usage recorded to ensure all 
ƉĂƚŝĞŶƚƐŝĚĞŶƚŝĨŝĞĚǁŚŽŚĂǀĞA? ?ŵŽŶƚŚƐĐŽŶƚŝŶƵŽƵƐƐƚĞƌŽŝĚ ?dŚĞĨŽůůŽǁŝŶŐĂƌĞĚŽĐƵŵĞŶƚĞĚŝŶŽƵƚƉĂƚŝĞŶƚ
review : number of liquid stools per day, abdominal pain or mass, general well-being, psychological 
ĐŽŶĐĞƌŶƐ ?ǁĞŝŐŚƚůŽƐƐ ?ƐŵŽŬŝŶŐƐƚĂƚƵƐ ?ŽŶĞĚĞŶƐŝƚŽŵĞƚƌǇŽĨĨĞƌĞĚƌŽƵƚŝŶĞůǇƚŽĂůůƉĂƚŝĞŶƚƐ ?A䠃?ŵŽŶƚŚƐ
ĐŽŶƚŝŶƵŽƵƐƐƚĞƌŽŝĚ ? ?ŶŶƵĂůĚĂƚĂŝƐĐŽůůĞĐƚĞĚ ?ƉƌĞƐĞŶƚĞĚ PA?ƉĂƚŝĞŶƚƐǁŚŽƌĞŵĂŝŶŽŶƐƚĞƌŽŝĚƐ ?A䠃?ŵŽnths), 
% these patients discussed at MDT, % start additional therapy (eg immunosuppressives, anti-TN, surgery) 
Care of patients aged 16 years and younger within adult services: Defined access to a consultant 
paediatric gastroenterologist/consultant paediatrican with interest in gastroenterology, working with an 
adult consultant gastroenterologist with interest in adolescents, Inpatients are looked after in an age-
appropriate environment, Patients have access to IBD nurse specialist with suitable paediatric experience, 
dŚĞƚĞĂŵƉƌŽǀŝĚŝŶŐĐĂƌĞĨŽƌƉĂƚŝĞŶƚƐA䜀  ? ?ǇĞĂƌƐ ?ǁŽƌŬǁŝƚŚŝŶĂƉĂĞĚŝĂƚƌŝĐĐůŝŶŝĐĂůŶĞƚǁŽƌŬ ?WĂĞĚŝĂƚƌŝĐ
patients undergo endoscopy in an age-appropriate environment, carried out by someone with training or 
extensive experience in paediatric endoscopy, Team providing care have access to a surgeon, 
anaesthetist with appropriate paediatric training, Defined access to dietitian with paediatric experience 
There is defined access to a radiologist with suitable paediatric experience  
Transitional care: Transitional care service for young people to support their transfer to adult services by 
18-19 years, Named coordinator responsible for preparation/oversight of transitional care, IBD service 
has a joint transition clinic with paediatric services, Direct referral (not via GP) available for specialist 
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endocrinology review (concerns about growth and/or pubertal status), IBD service has a specific 
paediatric to adult transition policy, Staff can refer to psychological services, Close working relationship 
with psychological services in clinics/ward, Each young person with IBD has individual transition plan, 
Age-appropriate written and verbal advice provided on day to day management of symptoms/treatment, 
Support education provided on sexual health in young people with IBD 
SECTION 5: RESEARCH, EDUCATION AND AUDIT  
  Register of patients under the care of the IBD service: IBD service has a searchable database or registry of 
adult IBD patients, Database is updated: clinical data about IBD patients receiving hospital care, patients 
on biological therapy, patients on all immunosuppressants (including biological therapies), clinical data 
about all patients with a diagnosis of IBD 
Participation in audit: Service participates in: national IBD audit, in the national IBD audit and results are 
fed back to the service. An action plan is completed, Patient surveys are carried out annually, All IBD 
inpatient deaths are reviewed by the IBD team, an action plan is formulated, action plan implementation 
reviewed at least annually, Service participates in the national IBD audit, completes an action plan and 
ensures monitoring of actions or changes, Mortality/morbidity meetings attended by MDT to discuss 
deaths and outcomes of surgery, Regular patient survey, action plan produced, required changes 
completed 
Training and education: Education opportunities for all medical/nursing staff, IBD team provides IBD 
training for primary care on an ad hoc basis, Advanced nursing practitioners within IBD team have 
regular, multidisciplinary training schedule, Attendance is audited, protected time for training provided, 
Primary care practitioners wishing to provide IBD services are named members of the IBD team 
Research:  IBD service is: part of a clinical trials network (UKCRN), has enrolled patients in IBD trial (<two 
years), All service members encouraged to participate in research (monetary support, flexible working) 
Service development: Annual review of IBD service carried out, IBD team in one or more clinical network 
arrangements with neighbouring IBD services, Annual review is attended by a MDT of relevant 
professionals, Annual action plan completed and achievement of the actions reviewed 
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Table A10: Fields collected in the IBD NCA (Biologics) 
BIOLOGIC AUDIT QUESTIONNAIRE (all questions mandatory) 
Six questionnaires: CD(A), CD(I), UC(A), UC(I), IBDU(A), IBDU(I), plus follow-up questionnaire 
ǆƚƌĂĐƚƐďĞůŽǁƚĂŬĞŶĨƌŽŵƌŽŚŶ ?ƐĚŝƐĞĂƐĞĚĂůŝŵƵŵĂď ? ? ? ?ƋƵĞƐƚŝŽŶŶĂŝƌĞ 
PATIENT DEMOGRAPHS
Surname, Forename, Gender, Date Of birth, NHS number (or Community Health Index Number, or Health 
and social care number), Postcode 
IBD DISEASE DETAILS 
ŝĂŐŶŽƐŝƐ ?ƌŽŚŶ ?ƐŝƐĞĂƐĞ ? 
Maximal disease distribution at the time of decision to initiate biologic therapy (Terminal ileum, colonic, 
ileocolonic, none of these), Any part of the gut proximal to the terminal ileum (Y/N), Perianal involvement 
(Y/N), Date of diagnosis  
INITIAL ANTI-TNF TREATMENT
Is the patient a new starter or already established on ant-TNF treatment for IBD (new starter/already 
established), Informed consent to receive anti-TNF treatment taken (Y/N),  
Initial anti-TNF treatment type (infliximab), If new starter, date of decision to start, Date of initial loading 
dose, Clinical indication for this treatment (severe perianal CD, active luminal CD, not known, other), 
Patient receiving any concomitant therapies for the management of IBD at the time of this treatment 
(Y/N), If yes select from (list (methotrexate, antibiotics, steroids etc), Has the patient previously failed to 
respond or are intolerant to immunosuppressive drugs/corticosteroids (Y/N), If yes select from list (anti-
TNF, methotrexate, antibiotics, steroids etc) 
ADALIMUMAB TREATMENT
Induction dose, Planned maintenance dose, Any acute reactions to injections during induction regime 
(Y/N), If yes select from (list (fever, nausea, rash etc), Disease severity score,
* 
Disease severity (severe, 
moderate, mild) 
BIOLOGIC AUDIT Generic follow-up questionnaire (all questions mandatory) 
PATIENT IDENTIFIER 
NHS, CHI or HSCN number 
TREATMENT SELECTION  
Date of initial loading dose, Was the patient: seen for follow up, lost to follow up, transitioned to adult 
care, transferred to another service, deceased 
ADALIMUMAB REVIEW DETAILS  
Date of Adalimumab review,  Review of treatment plan (continue/stop Adalimumab treatment), If 
continue treatment (every week/every other week), If continue treatment dose (80mg/40mg), If stop 
treatment (treatment effective and discontinued, loss of response, poor response, side effects/adverse 
events, patient choice, patient became pregnant, other) 
INFLIXIMAB INFUSION DETAILS
Date of Infliximab infusion, Current Infliximab dose number, Infliximab dose at this infusion (5 or 10 
mg/kg, other), Continued Infliximab treatment plan (continue/stop Infliximab treatment), If stop 
treatment (treatment effective and discontinued, loss of response, poor response, side effects/adverse 
events, patient became pregnant, patient choice, other) 
ADDITIONAL SECTION FOR BOTH ADALIMUMAB AND INFLIXIMAB  
Were any acute infusion/injection reactions recorded (Y/N), If yes select from list (e.g. fever, itching, 
nausea etc),  Is patient currently receiving any other medication for the management of their IBD (list of 
alternative medications), Adverse events since last review (Y/N), If yes select from list (e.g. death, 
malignancy, infection, drug-induced lupus etc), Disease severity score (severe, moderate, mild) 
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Table A11: Fields collected in the IBD Patient questionnaire 
ADMISSION TO HOSPITAL 
 
 Was your most recent hospital stay planned in advance or an emergency 
HOSPITAL AND WARD
 
 While in hospital, did you ever stay in a specialist ward that cared mainly for patients with bowel 
ĐŽŶĚŝƚŝŽŶƐ ?Ă “ŐĂƐƚƌŽĞŶƚĞƌŽůŽŐǇ ?ǁĂƌĚ ? ?tŚĞŶǇŽƵǁĞƌĞĨŝƐƚĂĚŵŝƚƚĞĚƚŽĂ bed on a ward, did you share 
a sleeping area, for example a room or bay, with patients of the opposite sex? During your stay in 
hospital, how many wards did you stay in? While staying in hospital, did you ever use the same bathroom 
or shower area as patients of the opposite sex? When you needed to use a toilet or bathroom, was there 
a suitable one located close by? For most of your stay, what type of room or ward were you in? Were you 
given enough privacy while you were on the ward In your opinion, how clean was the hospital room or 
ward that you were in? How clean were the toilets and bathrooms that you used in hospital? Did you see 
posters or leaflets on the ward asking patients and visitors to wash their hands or to use hand wash gels? 
Were hand-wash gels available for patients and visitors to use? 
FOOD 
 How would you rate the hospital food? Was the hospital food appetising? How much food were you 
given? Were you offered a choice of food? Do you have any special dietary requirements (e.g. vegetarian, 
diabetic, food allergies)? Was the hospital food suitable for your dietary needs? Did you get enough help 
from staff to eat your meals? During your stay in hospital, did you have a visit from a dietitian? Were you 
given extra nutritional supplements to take (e.g. special drinks or foods) at any time during your 
admission to help maintain or gain weight? Did you receive any special feed via a tube (e.g. placed 
through the nose) or directly into your veins during your admission? 
DOCTORS 
  Was there one doctor in overall charge of your care?, During your stay in hospital, did the doctor in 
overall charge of your care (consultant) arrange for you to be seen by another specialist (i.e. a different 
medical or surgical specialist), When you had important questions to ask a doctor, did you get answers 
that you could understand? If you had any worries or fears about your condition or treatment, did a 
doctor discuss them with you? Did you have confidence and trust in the doctors treating you? How would 
you rate the courtesy of your doctors? In your opinion, did the doctors who treated you know enough 
about your condition or treatment? As far as you know, did doctors wash or clean their hands between 
touching patients? 
NURSES 
  When you had important questions to ask a nurse, did you get answers that you could understand? If you 
had any worries or fears about your condition or treatment, did a nurse discuss them with you? Did you 
have confidence and trust in the nurses treating you? In your opinion, were there enough nurses on duty 
to care for you in hospital? If you ever needed to talk to a nurse, did you get the opportunity to do so? 
Apart from the regular nursing staff on the ward did you receive a visit from a specialist nurse while you 
ǁĞƌĞŝŶŚŽƐƉŝƚĂů ?ĞŐ ? ‘/EƵƌƐĞ ? ? ‘ůŝŶŝĐĂůEƵƌƐĞ^ƉĞĐŝĂůŝƐƚ ? ? ‘EƵƌƐĞŽŶƐƵůƚĂŶƚ ?Žƌ ‘^ƚŽŵĂEƵƌƐĞ ? ?,Žǁ
would you rate the courtesy of your nurses? In your opinion, did the nurses who treated you know 
enough about your condition or treatment? As far as you know, did nurses wash or clean their hands 
between touching patients?  
YOUR CARE AND TREATMENTS 
  Sometimes in a hospital, a member of staff will say one thing and another will say something quite 
different. Did this happen to you? Were you involved as much as you wanted to be in decisions about 
your care and treatment? How much information about your condition or treatment was given to you? 
While you were in hospital, were you told your diagnosis (explanation of what was wrong with you)? Was 
your diagnosis explained to you in a way that you could understand? If your family or someone else close 
to you wanted to talk to a doctor, did they have enough opportunity to do so? Did you find someone on 
the hospital staff to talk to about your worries and fears? Were you given enough privacy when 
discussing your condition or treatment? Were you given enough privacy when being examined or 
treated?  
PAIN 
  Were you ever in any pain? Do you think the hospital staff did everything they could to control your pain? 
When you had pain, was it usually severe, moderate or mild? During your stay in hospital, how much of 
the time were you in pain? Did you ever request pain relief medication? Overall, how much pain relief 
medication did you get? 
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OPERATIONS & PROCEDURES 
During your stay in hospital, did you have an operation or procedure? If yes: Beforehand, did a member 
of staff explain the risks and benefits of the operation or procedure in a way you could understand, 
Beforehand, did a member of staff explain what would be done during the operation or procedure? 
Beforehand, did a member of staff answer your questions about the operation or procedure in a way you 
could understand? After the operation or procedure, did a member of staff explain how the operation or 
procedure had gone in a way you could understand?  
LEAVING HOSPITAL 
Did you feel you were involved in decisions about your discharge from hospital? Were your family or 
someone close to you given enough notice about your discharge? Did a member of staff explain the 
purpose of the medicines you were to take at home in a way you could understand?  Did a member of 
staff tell you about medication side effects to watch for when you went home? Were you told how to 
take your medication in a way you could understand? Were you given clear written or printed 
information about your medicines? Did a member of staff tell you about any danger signals you should 
watch for after you went home? Did hospital staff take your family or home situation into account when 
planning your discharge? Did the doctors or nurses give your family or someone close to you all the 
information they needed to help care for you? Do you feel that you received enough information from 
the hospital on how to manage your condition after your discharge? Did you receive copies of letters sent 
between hospital doctors and your family doctor (GP)?  
OVERALL 
Overall, did you feel you were treated with respect and dignity while you were in the hospital? How 
would you rate how well the doctors and nurses worked together? Overall, were you treated with 
kindness and understanding while you were in the hospital? Overall, how would you rate the care you 
received? Would you recommend this hospital to your family and friends? During your hospital stay, were 
you ever asked to give your views on the quality of your care?   
ABOUT YOU OR YOUR CHILD 
Are you male or female? What was your year of birth? How old were you when you left full-time 
education? In the 12 months before this admission, how many days of (paid or unpaid) work or school 
have you had to miss as a result of your ulcerative colitis? Please enter the number in the box below  
ADOLESCENT SPECIFIC SECTION (AGED 13 TO 18 YEARS OF AGE) 
In your opinion, was the ward you stayed on suitable for a person of your age? Did the hospital staff 
involve you personally (not your family) enough in making decisions about your care? In your opinion, did 
the doctors know enough about how your condition affects people of your age? In your opinion, did the 
nurses who treated you know enough about how your condition affects people of your age? Did any 
member of staff give you advice about how to manage your IBD either at school or at work after you left 
hospital?  
YOUR OWN HEALTH STATE TODAY 
EQ-5D questionnaire: possible responses include (no problems, some problems, extreme problems) on 
Mobility, Self-care, Usual activities, Pain/discomfort, Anxiety/depression.  Do you have any of the 
following long-standing conditions in addition to IBD?  
WHO HAS COMPLETED THIS SURVEY 
I completed the questionnaire myself and I am aged 12 years or over, A parent/guardian/carer has 
completed the questionnaire on behalf of child who is under the age of 12 years 
OTHER COMMENTS 
If there is anything else you would like to tell us about your experiences in the hospital, please do so here.  
Was there anything particularly good about your hospital care? Was there anything that could be 
improved? Any other comments? 
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